Angeles Alvarez Secord | Scholars@Duke

Angeles Alvarez Secord
Professor of Obstetrics and Gynecology

My primary research interest has focused on angiogenesis, molecular signatures, clinical trial development, and ovarian cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically on anti-angiogenic therapy and molecular tumor signatures to direct therapy in patients with ovarian cancer to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian, and cervical cancers as well as for benign gynecologic conditions.

Current Appointments & Affiliations

Professor of Obstetrics and Gynecology, Obstetrics and Gynecology, Gynecologic Oncology, Obstetrics and Gynecology 2013
Member of the Duke Cancer Institute, Duke Cancer Institute, Institutes and Centers 1994

Contact Information

25172 Morris Bldg, Durham, NC 27710
Box 3079 Med Ctr, Durham, NC 27710
secor002@mc.duke.edu (919) 684-3765

Background
Education, Training, & Certifications
- Resident, Obstetrics & Gynecology, Duke University 1994 - 1998
- M.D., University of Washington 1994
Previous Appointments & Affiliations
- Associate Professor of Obstetrics and Gynecology, Obstetrics and Gynecology, Gynecologic Oncology, Obstetrics and Gynecology 2009 - 2013
- Associate Professor of Obstetrics and Gynecology, Obstetrics and Gynecology, Gynecologic Oncology, Obstetrics and Gynecology 2007 - 2009
- Assistant Professor of Obstetrics and Gynecology, Obstetrics and Gynecology, Gynecologic Oncology, Obstetrics and Gynecology 2002 - 2007
- Associate in the Department of Obstetrics and Gynecology, Obstetrics and Gynecology, Gynecologic Oncology, Obstetrics and Gynecology 1998 - 2002
Research
Selected Grants
External Relationships
- Aravive
- AstraZeneca
- Genentech, Inc (Roche Holding)
- GlaxoSmithKline
- Myriad Genetics, Inc
- OncoQuest - Quest Pharma
- Onconova
- Regeneron Pharmaceuticals
- VBL Therapeutics
Publications & Artistic Works
Selected Publications
- Academic Articles
  - Montes de Oca, Mary Katherine, Benjamin B. Albright, Angeles Alvarez Secord, Laura J. Havrilesky, and Haley A. Moss. “Adjuvant treatment and outcomes for patients with stage IIIA grade 1 endometrioid endometrial cancer.” International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society 31, no. 12 (December 2021): 1549–56. https://doi.org/10.1136/ijgc-2021-002884.
    Full Text
  - Cobb, Lauren Patterson, Sharareh Siamakpour-Reihani, Dadong Zhang, Xiaodi Qin, Kouros Owzar, Chunxiao Zhou, Thomas P. Conrads, et al. “Obesity and altered angiogenic-related gene expression in endometrial cancer.” Gynecol Oncol 163, no. 2 (November 2021): 320–26. https://doi.org/10.1016/j.ygyno.2021.08.010.
    Full Text Link to Item
  - Gray, Heidi J., and Angeles Alvarez Secord. “Society of Gynecologic Oncology (SGO) 2021 meeting report: Scaling new heights with innovative cancer care.” Gynecol Oncol 163, no. 1 (October 2021): 5–10. https://doi.org/10.1016/j.ygyno.2021.04.022.
    Full Text Link to Item
  - Moss, Haley A., Jessica A. Perhanidis, Laura J. Havrilesky, and Angeles Alvarez Secord. “Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.” Gynecol Oncol 163, no. 1 (October 2021): 50–56. https://doi.org/10.1016/j.ygyno.2021.07.026.
    Full Text Link to Item
  - Alvarez Secord, Angeles, David M. O’Malley, Anil K. Sood, Shannon N. Westin, and Joyce F. Liu. “Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.” Gynecol Oncol 162, no. 2 (August 2021): 482–95. https://doi.org/10.1016/j.ygyno.2021.05.018.
    Full Text Link to Item
  - Cohn, David E., Angeles Alvarez Secord, and Heidi Gray. “Abstracts for the 2021 Society of Gynecologic Oncology 52nd Annual Meeting on Women's Cancer Foreword.” Gynecologic Oncology 162 (August 2021): S1–S1.
    Link to Item
  - Gatta, Luke A., Paula S. Lee, Jennifer B. Gilner, Jeremy M. Weber, LaMani Adkins, Julia R. Salinaro, Ashraf S. Habib, et al. “Placental uterine artery embolization followed by delayed hysterectomy for placenta percreta: A case series.” Gynecol Oncol Rep 37 (August 2021): 100833. https://doi.org/10.1016/j.gore.2021.100833.
    Full Text Link to Item
  - Havrilesky, Laura J., Amelia L. Scott, Brittany A. Davidson, Angeles Alvarez Secord, Jui-Chen Yang, F Reed Johnson, Juan Marcos Gonzalez, and Shelby D. Reed. “The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens.” Gynecol Oncol 162, no. 2 (August 2021): 440–46. https://doi.org/10.1016/j.ygyno.2021.05.022.
    Full Text Link to Item
  - Puechl, Allison M., Daniel Spinosa, Andrew Berchuck, Angeles Alvarez Secord, Kerry E. Drury, Gloria Broadwater, Janice Wong, et al. “Molecular Classification to Prognosticate Response in Medically Managed Endometrial Cancers and Endometrial Intraepithelial Neoplasia.” Cancers (Basel) 13, no. 11 (June 7, 2021). https://doi.org/10.3390/cancers13112847.
    Full Text Link to Item
  - Arend, Rebecca C., Bradley J. Monk, Thomas J. Herzog, Kathleen N. Moore, Ronnie Shapira-Frommer, Jonathan A. Ledermann, Krishnansu S. Tewari, et al. “Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer.” Gynecol Oncol 161, no. 2 (May 2021): 496–501. https://doi.org/10.1016/j.ygyno.2021.02.014.
    Full Text Link to Item
  - Buechel, Megan E., Danielle Enserro, Robert A. Burger, Mark F. Brady, Katrina Wade, Angeles Alvarez Secord, Andrew B. Nixon, et al. “Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).” Gynecol Oncol 161, no. 2 (May 2021): 382–88. https://doi.org/10.1016/j.ygyno.2021.02.032.
    Full Text Link to Item
  - Leslie, Kimberly K., Virginia L. Filiaci, Adrianne R. Mallen, Kristina W. Thiel, Eric J. Devor, Katherine Moxley, Debra Richardson, et al. “Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.” Gynecol Oncol 161, no. 1 (April 2021): 113–21. https://doi.org/10.1016/j.ygyno.2021.01.025.
    Full Text Link to Item
  - Hagemann, Ian S., Wei Deng, Richard J. Zaino, Matthew A. Powell, Camille Gunderson, Casey Cosgrove, Cara Mathews, et al. “The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women.” Gynecol Oncol 160, no. 3 (March 2021): 660–68. https://doi.org/10.1016/j.ygyno.2020.12.040.
    Full Text Link to Item
  - Schwartz, Amanda R., David B. Bartlett, Johanna L. Johnson, Gloria Broadwater, Meghan Channell, Kimberly C. Nolte, Patricia A. Wilkes, Kim M. Huffman, and Angeles Alvarez Secord. “A Pilot Study of Home-Based Exercise and Personalized Nutrition Counseling Intervention in Endometrial Cancer Survivors.” Front Oncol 11 (2021): 669961. https://doi.org/10.3389/fonc.2021.669961.
    Full Text Link to Item
  - Batinic-Haberle, Ines, Artak Tovmasyan, Zhiqing Huang, Weina Duan, Li Du, Sharareh Siamakpour-Reihani, Zhipeng Cao, Huaxin Sheng, Ivan Spasojevic, and Angeles Alvarez Secord. “H2O2-Driven Anticancer Activity of Mn Porphyrins and the Underlying Molecular Pathways.” Oxid Med Cell Longev 2021 (2021): 6653790. https://doi.org/10.1155/2021/6653790.
    Full Text Open Access Copy Link to Item
  - Watson, Catherine H., Laura J. Fish, Margaret Falkovic, Karen Monuszko, Amelia Lorenzo, Laura J. Havrilesky, Angeles Alvarez Secord, and Brittany A. Davidson. “Adherence to Oral Anticancer Therapeutics in the Gynecologic Oncology Population.” Obstet Gynecol 136, no. 6 (December 2020): 1145–53. https://doi.org/10.1097/AOG.0000000000004170.
    Full Text Link to Item
  - Gonzalez, Rafael, Laura J. Havrilesky, Evan R. Myers, Angeles Alvarez Secord, Joseph A. Dottino, Andrew Berchuck, and Haley A. Moss. “Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer.” Gynecol Oncol 159, no. 2 (November 2020): 483–90. https://doi.org/10.1016/j.ygyno.2020.08.003.
    Full Text Link to Item
  - Son, Ji, Laura M. Chambers, Caitlin Carr, Chad M. Michener, Meng Yao, Anna Beavis, Ting-Tai Yen, et al. “Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion.” Int J Gynecol Cancer 30, no. 11 (November 2020): 1738–47. https://doi.org/10.1136/ijgc-2020-001454.
    Full Text Link to Item
  - Watson, Catherine H., Lindsay Soo, Brittany A. Davidson, Laura J. Havrilesky, Paula S. Lee, Leah J. McNally, Rebecca A. Previs, Angeles Alvarez Secord, Andrew Berchuck, and Noah D. Kauff. “Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices.” Int J Gynecol Cancer 30, no. 10 (October 2020): 1583–88. https://doi.org/10.1136/ijgc-2020-001536.
    Full Text Link to Item
  - Watson, Catherine H., and Angeles Alvarez Secord. “Durable response to hormonal therapy in a patient with rapidly progressive low-grade serous ovarian cancer: A case report.” Gynecol Oncol Rep 33 (August 2020): 100598. https://doi.org/10.1016/j.gore.2020.100598.
    Full Text Link to Item
  - Fader, Amanda N., Dana M. Roque, Eric Siegel, Natalia Buza, Pei Hui, Osama Abdelghany, Setsuko Chambers, et al. “Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.” Clin Cancer Res 26, no. 15 (August 1, 2020): 3928–35. https://doi.org/10.1158/1078-0432.CCR-20-0953.
    Full Text Link to Item
  - Monk, Bradley J., Robert L. Coleman, Kathleen N. Moore, Thomas J. Herzog, Angeles Alvarez Secord, Ursula A. Matulonis, Brian M. Slomovitz, Saketh R. Guntupalli, and David M. O’Malley. “COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies.” Gynecol Oncol 158, no. 1 (July 2020): 34–36. https://doi.org/10.1016/j.ygyno.2020.04.703.
    Full Text Link to Item
  - Pothuri, Bhavana, Angeles Alvarez Secord, Deborah K. Armstrong, John Chan, Amanda N. Fader, Warner Huh, Joshua Kesterson, et al. “Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis.” Gynecol Oncol 158, no. 1 (July 2020): 16–24. https://doi.org/10.1016/j.ygyno.2020.04.694.
    Full Text Link to Item
  - Duska, L. R., G. R. Petroni, N. Varhegyi, J. Brown, D. Jelovac, K. N. Moore, W. P. McGuire, C. Darus, L. M. Barroilhet, and A. A. Secord. “A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.” Gynecologic Oncology 157, no. 3 (June 2020): 585–92. https://doi.org/10.1016/j.ygyno.2019.10.014.
    Full Text
  - Salinaro, Julia Rose, Kourtnie McQuillen, Megan Stemple, Robert Boccaccio, Jessie Ehrisman, Amelia M. Lorenzo, Laura Havrilesky, et al. “Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced epithelial ovarian cancer.” Int J Gynecol Cancer 30, no. 4 (April 2020): 491–97. https://doi.org/10.1136/ijgc-2019-000980.
    Full Text Link to Item
  - Alvarez Secord, Angeles, Kirsten Bell Burdett, Kouros Owzar, David Tritchler, Alexander B. Sibley, Yingmiao Liu, Mark D. Starr, et al. “Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.” Clin Cancer Res 26, no. 6 (March 15, 2020): 1288–96. https://doi.org/10.1158/1078-0432.CCR-19-0226.
    Full Text Link to Item
  - Bixel, K., M. Vetter, B. Davidson, A. Berchuck, D. Cohn, L. Copeland, J. M. Fowler, et al. “Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.” Gynecol Oncol 156, no. 3 (March 2020): 530–34. https://doi.org/10.1016/j.ygyno.2019.12.016.
    Full Text Link to Item
  - Coleman, R. L., N. M. Spirtos, D. Enserro, T. J. Herzog, P. Sabbatini, D. K. Armstrong, J. W. Kim, et al. “Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.” Obstetrical and Gynecological Survey 75, no. 3 (March 1, 2020): 165–66. https://doi.org/10.1097/OGX.0000000000000777.
    Full Text
  - Beavis, Anna L., Ting-Tai Yen, Rebecca L. Stone, Stephanie L. Wethington, Caitlin Carr, Ji Son, Laura Chambers, et al. “Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?” Gynecologic Oncology 156, no. 3 (March 2020): 568–74. https://doi.org/10.1016/j.ygyno.2019.12.028.
    Full Text
  - Havrilesky, Laura J., Stephanie Lim, Jessie A. Ehrisman, Amelia Lorenzo, Angeles Alvarez Secord, Jui-Chen Yang, F Reed Johnson, Juan Marcos Gonzalez, and Shelby D. Reed. “Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.” Gynecol Oncol 156, no. 3 (March 2020): 561–67. https://doi.org/10.1016/j.ygyno.2020.01.026.
    Full Text Link to Item
  - Oza, Amit M., Ursula A. Matulonis, Angeles Alvarez Secord, John Nemunaitis, Lynda D. Roman, Sarah P. Blagden, Susana Banerjee, et al. “A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.” Clin Cancer Res 26, no. 5 (March 1, 2020): 1009–16. https://doi.org/10.1158/1078-0432.CCR-19-1638.
    Full Text Link to Item
  - Siamakpour-Reihani, Sharareh, Lauren Patterson Cobb, Chen Jiang, Dadong Zhang, Rebecca A. Previs, Kouros Owzar, Andrew B. Nixon, and Angeles Alvarez Secord. “Differential expression of immune related genes in high-grade ovarian serous carcinoma.” Gynecol Oncol 156, no. 3 (March 2020): 662–68. https://doi.org/10.1016/j.ygyno.2019.12.019.
    Full Text Link to Item
  - Herzog, Thomas J., Angeles Alvarez Secord, Robert L. Coleman, and R Wendel Naumann. “European society of medical oncology (ESMO) 2019 meeting report features practice changing data in gynecologic malignancies.” Gynecol Oncol 156, no. 2 (February 2020): 265–70. https://doi.org/10.1016/j.ygyno.2019.11.010.
    Full Text Link to Item
  - Deutsch, Gary B., Jeremiah L. Deneve, Mazin F. Al-Kasspooles, Valentine N. Nfonsam, Camille C. Gunderson, Angeles Alvarez Secord, Phillip Rodgers, et al. “Intellectual Equipoise and Challenges: Accruing Patients With Advanced Cancer to a Trial Randomizing to Surgical or Nonsurgical Management (SWOG S1316).” Am J Hosp Palliat Care 37, no. 1 (January 2020): 12–18. https://doi.org/10.1177/1049909119851471.
    Full Text Link to Item
  - Havrilesky, Laura J., Jui-Chen Yang, Paula S. Lee, Angeles Alvarez Secord, Jessie A. Ehrisman, Brittany Davidson, Andrew Berchuck, Kathleen M. Darcy, G Larry Maxwell, and Shelby D. Reed. “Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer.” Cancer 125, no. 24 (December 15, 2019): 4399–4406. https://doi.org/10.1002/cncr.32447.
    Full Text Link to Item
  - Havrilesky, L. J., J. C. Yang, P. S. Lee, A. A. Secord, J. A. Ehrisman, B. Davidson, A. Berchuck, K. M. Darcy, G. L. Maxwell, and S. D. Reed. “Patient Preferences for Attributes of Primary Surgical Debulking Versus Neoadjuvant Chemotherapy for Treatment of Newly Diagnosed Ovarian Cancer.” Obstetrical and Gynecological Survey 74, no. 12 (December 1, 2019): 718–19. https://doi.org/10.1097/OGX.0000000000000743.
    Full Text
  - Coleman, Robert L., Nick M. Spirtos, Danielle Enserro, Thomas J. Herzog, Paul Sabbatini, Deborah K. Armstrong, Jae-Weon Kim, et al. “Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.” N Engl J Med 381, no. 20 (November 14, 2019): 1929–39. https://doi.org/10.1056/NEJMoa1902626.
    Full Text Link to Item
  - Walker, J. L., M. F. Brady, L. Wenzel, G. F. Fleming, H. Q. Huang, P. A. Disilvestro, K. Fujiwara, et al. “Randomized clinical trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG oncology/gynecologic oncology group study.” Obstetrical and Gynecological Survey 74, no. 8 (August 1, 2019): 474–76. https://doi.org/10.1097/01.ogx.0000576976.42254.c2.
    Full Text
  - Gaillard, Stéphanie L., Kaitlyn J. Andreano, Laurie M. Gay, Meghan Steiner, Matthew S. Jorgensen, Brittany Anne Davidson, Laura J. Havrilesky, et al. “Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies.” Gynecol Oncol 154, no. 1 (July 2019): 199–206. https://doi.org/10.1016/j.ygyno.2019.04.010.
    Full Text Link to Item
  - Secord, Angeles Alvarez, Michael McCollum, Brittany A. Davidson, Gloria Broadwater, Robert Squatrito, Laura J. Havrilesky, Anne C. Gabel, et al. “Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.” Gynecol Oncol 153, no. 3 (June 2019): 555–61. https://doi.org/10.1016/j.ygyno.2019.03.246.
    Full Text Link to Item
  - Secord, Angeles Alvarez. “Ovarian cancer: time to move beyond one size fits all.” Lancet Oncol 20, no. 6 (June 2019): 754–55. https://doi.org/10.1016/S1470-2045(19)30285-2.
    Full Text Link to Item
  - Walker, Joan L., Mark F. Brady, Lari Wenzel, Gini F. Fleming, Helen Q. Huang, Paul A. DiSilvestro, Keiichi Fujiwara, et al. “Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.” J Clin Oncol 37, no. 16 (June 1, 2019): 1380–90. https://doi.org/10.1200/JCO.18.01568.
    Full Text Link to Item
  - Veade, Ashley E., Jonathan Foote, Jessie Ehrisman, Gloria Broadwater, Brittany A. Davidson, Paula S. Lee, Angeles Alvarez Secord, Andrew Berchuck, and Laura J. Havrilesky. “Associations between lymphovascular space invasion, nodal recurrence, and survival in patients with surgical stage I endometrioid endometrial adenocarcinoma.” World J Surg Oncol 17, no. 1 (May 10, 2019): 80. https://doi.org/10.1186/s12957-019-1620-x.
    Full Text Link to Item
  - Lim, Stephanie L., Laura J. Havrilesky, Ashraf S. Habib, and Angeles Alvarez Secord. “Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy.” Gynecol Oncol 153, no. 2 (May 2019): 376–80. https://doi.org/10.1016/j.ygyno.2019.01.025.
    Full Text Link to Item
  - Moore, K. N., A. A. Secord, and M. A. Geller. “Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial (vol 20, pg 636, 2019).” Lancet Oncology 20, no. 5 (May 1, 2019): E242–E242.
    Link to Item
  - Moore, Kathleen N., Angeles Alvarez Secord, Melissa A. Geller, David Scott Miller, Noelle Cloven, Gini F. Fleming, Andrea E. Wahner Hendrickson, et al. “Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.” Lancet Oncol 20, no. 5 (May 2019): 636–48. https://doi.org/10.1016/S1470-2045(19)30029-4.
    Full Text Link to Item
  - Dottino, Joseph A., Haley A. Moss, Karen H. Lu, Angeles A. Secord, and Laura J. Havrilesky. “U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.” Obstet Gynecol 133, no. 4 (April 2019): 795–802. https://doi.org/10.1097/AOG.0000000000003171.
    Full Text Link to Item
  - Moore, Kathleen, John K. Chan, Angeles Alvarez Secord, Manish R. Patel, Timothy Callahan, Wei Guo, and Zhi-Yi Zhang. “Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.” Cancer Chemother Pharmacol 83, no. 4 (April 2019): 717–26. https://doi.org/10.1007/s00280-019-03774-w.
    Full Text Link to Item
  - Puechl, Allison M., James Edwards, Anuj Suri, John Nakayama, Sarah Bean, Paola Gehrig, Erin Saks, et al. “The association between progesterone receptor expression and survival in women with adult granulosa cell tumors.” Gynecol Oncol 153, no. 1 (April 2019): 74–79. https://doi.org/10.1016/j.ygyno.2019.01.016.
    Full Text Link to Item
  - “Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma: Correction.” Obstetrics & Gynecology 133, no. 4 (April 2019): 830–830. https://doi.org/10.1097/aog.0000000000003212.
    Full Text
  - Davidson, Brittany A., Gloria Broadwater, Aleia Crim, Robert Boccacio, Kristin Bixel, Floor Backes, Rebecca A. Previs, et al. “Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy.” Gynecol Oncol 152, no. 3 (March 2019): 554–59. https://doi.org/10.1016/j.ygyno.2018.12.011.
    Full Text Link to Item
  - Foote, Jonathan R., Angeles Alvarez Secord, Margaret I. Liang, Jessie A. Ehrisman, David E. Cohn, Elizabeth Jewell, and Laura J. Havrilesky. “Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.” Gynecol Oncol 152, no. 3 (March 2019): 445–51. https://doi.org/10.1016/j.ygyno.2018.11.028.
    Full Text Link to Item
  - Previs, Rebecca Ann, and Angeles Alvarez Secord. “Ovarian Cancer: Clinical Trial Breakthroughs and Impact on Management.” Obstet Gynecol Clin North Am 46, no. 1 (March 2019): 67–88. https://doi.org/10.1016/j.ogc.2018.09.005.
    Full Text Link to Item
  - Rose, Peter G., James J. Java, Ritu Salani, Melissa A. Geller, Angeles Alvarez Secord, Krishnansu S. Tewari, David P. Bender, et al. “Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma.” Obstet Gynecol 133, no. 2 (February 2019): 245–54. https://doi.org/10.1097/AOG.0000000000003086.
    Full Text Link to Item
  - Lim, Stephanie L., Haley A. Moss, Angeles Alvarez Secord, Paula S. Lee, Laura J. Havrilesky, and Brittany A. Davidson. “Hysterectomy with sentinel lymph node biopsy in the setting of pre-operative diagnosis of endometrial intraepithelial neoplasia: A cost-effectiveness analysis.” Gynecol Oncol 151, no. 3 (December 2018): 506–12. https://doi.org/10.1016/j.ygyno.2018.09.020.
    Full Text Link to Item
  - Monk, Bradley J., James T. Kauderer, Katherine M. Moxley, Albert J. Bonebrake, Summer B. Dewdney, Angeles Alvarez Secord, Frederick R. Ueland, Carolyn M. Johnston, and Carol Aghajanian. “A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.” Gynecol Oncol 151, no. 3 (December 2018): 422–27. https://doi.org/10.1016/j.ygyno.2018.10.001.
    Full Text Link to Item
  - Tew, William P., Michael W. Sill, Joan L. Walker, Angeles Alvarez Secord, Albert J. Bonebrake, Jeanne M. Schilder, Ashley Stuckey, Laurel Rice, Krishnansu S. Tewari, and Carol A. Aghajanian. “Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.” Gynecol Oncol 151, no. 2 (November 2018): 257–63. https://doi.org/10.1016/j.ygyno.2018.08.027.
    Full Text Link to Item
  - DiSilvestro, Paul, and Angeles Alvarez Secord. “Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time?” Cancer Treat Rev 69 (September 2018): 53–65. https://doi.org/10.1016/j.ctrv.2018.06.001.
    Full Text Link to Item
  - Aghajanian, Carol, Virginia Filiaci, Don S. Dizon, Jay W. Carlson, Matthew A. Powell, Angeles Alvarez Secord, Krishnansu S. Tewari, et al. “A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.” Gynecol Oncol 150, no. 2 (August 2018): 274–81. https://doi.org/10.1016/j.ygyno.2018.05.018.
    Full Text Link to Item
  - Chan, John K., William Brady, Bradley J. Monk, Jubilee Brown, Mark S. Shahin, Peter G. Rose, Jae-Hoon Kim, Angeles Alvarez Secord, Joan L. Walker, and David M. Gershenson. “A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).” Gynecol Oncol 150, no. 2 (August 2018): 247–52. https://doi.org/10.1016/j.ygyno.2018.05.029.
    Full Text Link to Item
  - Fader, Amanda N., Dana M. Roque, Eric Siegel, Natalia Buza, Pei Hui, Osama Abdelghany, Setsuko K. Chambers, et al. “Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.” J Clin Oncol 36, no. 20 (July 10, 2018): 2044–51. https://doi.org/10.1200/JCO.2017.76.5966.
    Full Text Link to Item
  - Secord, Angeles Alvarez, Rebecca A. Previs, and Andrew B. Nixon. “Cabozantinib in ovarian clear cell cancers: UnMET expectations.” Gynecol Oncol 150, no. 1 (July 2018): 1–2. https://doi.org/10.1016/j.ygyno.2018.06.006.
    Full Text Link to Item
  - Ricketts, Christopher J., Aguirre A. De Cubas, Huihui Fan, Christof C. Smith, Martin Lang, Ed Reznik, Reanne Bowlby, et al. “The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.” Cell Rep 23, no. 12 (June 19, 2018): 3698. https://doi.org/10.1016/j.celrep.2018.06.032.
    Full Text Link to Item
  - Matei, Daniela, Sharad Ghamande, Lynda Roman, Angeles Alvarez Secord, John Nemunaitis, Merry Jennifer Markham, Kenneth P. Nephew, et al. “A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.” Clin Cancer Res 24, no. 10 (May 15, 2018): 2285–93. https://doi.org/10.1158/1078-0432.CCR-17-3055.
    Full Text Link to Item
  - Davidson, Brittany A., Jessie Ehrisman, Sara Abbott, Zach Harmon, Angeles A. Secord, Andrew Berchuck, Paula S. Lee, et al. “Prospective Evaluation of Lymph Node Processing at Staging Surgery for High-grade Endometrial Cancer.” Int J Gynecol Pathol 37, no. 3 (May 2018): 252–55. https://doi.org/10.1097/PGP.0000000000000418.
    Full Text Link to Item
  - Thorsson, Vésteinn, David L. Gibbs, Scott D. Brown, Denise Wolf, Dante S. Bortone, Tai-Hsien Ou Yang, Eduard Porta-Pardo, et al. “The Immune Landscape of Cancer.” Immunity 48, no. 4 (April 17, 2018): 812-830.e14. https://doi.org/10.1016/j.immuni.2018.03.023.
    Full Text Link to Item
  - Berger, Ashton C., Anil Korkut, Rupa S. Kanchi, Apurva M. Hegde, Walter Lenoir, Wenbin Liu, Yuexin Liu, et al. “A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.” Cancer Cell 33, no. 4 (April 9, 2018): 690-705.e9. https://doi.org/10.1016/j.ccell.2018.03.014.
    Full Text Link to Item
  - Liu, Yang, Nilay S. Sethi, Toshinori Hinoue, Barbara G. Schneider, Andrew D. Cherniack, Francisco Sanchez-Vega, Jose A. Seoane, et al. “Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas.” Cancer Cell 33, no. 4 (April 9, 2018): 721-735.e8. https://doi.org/10.1016/j.ccell.2018.03.010.
    Full Text Link to Item
  - Taylor, Alison M., Juliann Shih, Gavin Ha, Galen F. Gao, Xiaoyang Zhang, Ashton C. Berger, Steven E. Schumacher, et al. “Genomic and Functional Approaches to Understanding Cancer Aneuploidy.” Cancer Cell 33, no. 4 (April 9, 2018): 676-689.e3. https://doi.org/10.1016/j.ccell.2018.03.007.
    Full Text Link to Item
  - Wang, Zehua, Bo Yang, Min Zhang, Weiwei Guo, Zhiyuan Wu, Yue Wang, Lin Jia, et al. “lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer.” Cancer Cell 33, no. 4 (April 9, 2018): 706-720.e9. https://doi.org/10.1016/j.ccell.2018.03.006.
    Full Text Link to Item
  - Bailey, Matthew H., Collin Tokheim, Eduard Porta-Pardo, Sohini Sengupta, Denis Bertrand, Amila Weerasinghe, Antonio Colaprico, et al. “Comprehensive Characterization of Cancer Driver Genes and Mutations.” Cell 173, no. 2 (April 5, 2018): 371-385.e18. https://doi.org/10.1016/j.cell.2018.02.060.
    Full Text Link to Item
  - Chen, Han, Chunyan Li, Xinxin Peng, Zhicheng Zhou, John N. Weinstein, John N. Cancer Genome Atlas Research Network, and Han Liang. “A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples.” Cell 173, no. 2 (April 5, 2018): 386-399.e12. https://doi.org/10.1016/j.cell.2018.03.027.
    Full Text Link to Item
  - Ding, Li, Matthew H. Bailey, Eduard Porta-Pardo, Vesteinn Thorsson, Antonio Colaprico, Denis Bertrand, David L. Gibbs, et al. “Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics.” Cell 173, no. 2 (April 5, 2018): 305-320.e10. https://doi.org/10.1016/j.cell.2018.03.033.
    Full Text Link to Item
  - Hoadley, Katherine A., Christina Yau, Toshinori Hinoue, Denise M. Wolf, Alexander J. Lazar, Esther Drill, Ronglai Shen, et al. “Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer.” Cell 173, no. 2 (April 5, 2018): 291-304.e6. https://doi.org/10.1016/j.cell.2018.03.022.
    Full Text Link to Item
  - Huang, Kuan-Lin, R Jay Mashl, Yige Wu, Deborah I. Ritter, Jiayin Wang, Clara Oh, Marta Paczkowska, et al. “Pathogenic Germline Variants in 10,389 Adult Cancers.” Cell 173, no. 2 (April 5, 2018): 355-370.e14. https://doi.org/10.1016/j.cell.2018.03.039.
    Full Text Link to Item
  - Liu, Jianfang, Tara Lichtenberg, Katherine A. Hoadley, Laila M. Poisson, Alexander J. Lazar, Andrew D. Cherniack, Albert J. Kovatich, et al. “An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.” Cell 173, no. 2 (April 5, 2018): 400-416.e11. https://doi.org/10.1016/j.cell.2018.02.052.
    Full Text Link to Item
  - Malta, Tathiane M., Artem Sokolov, Andrew J. Gentles, Tomasz Burzykowski, Laila Poisson, John N. Weinstein, Bożena Kamińska, et al. “Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation.” Cell 173, no. 2 (April 5, 2018): 338-354.e15. https://doi.org/10.1016/j.cell.2018.03.034.
    Full Text Link to Item
  - Sanchez-Vega, Francisco, Marco Mina, Joshua Armenia, Walid K. Chatila, Augustin Luna, Konnor C. La, Sofia Dimitriadoy, et al. “Oncogenic Signaling Pathways in The Cancer Genome Atlas.” Cell 173, no. 2 (April 5, 2018): 321-337.e10. https://doi.org/10.1016/j.cell.2018.03.035.
    Full Text Link to Item
  - Campbell, Joshua D., Christina Yau, Reanne Bowlby, Yuexin Liu, Kevin Brennan, Huihui Fan, Alison M. Taylor, et al. “Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.” Cell Rep 23, no. 1 (April 3, 2018): 194-212.e6. https://doi.org/10.1016/j.celrep.2018.03.063.
    Full Text Link to Item
  - Chiu, Hua-Sheng, Sonal Somvanshi, Ektaben Patel, Ting-Wen Chen, Vivek P. Singh, Barry Zorman, Sagar L. Patil, et al. “Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context.” Cell Rep 23, no. 1 (April 3, 2018): 297-312.e12. https://doi.org/10.1016/j.celrep.2018.03.064.
    Full Text Link to Item
  - Gao, Qingsong, Wen-Wei Liang, Steven M. Foltz, Gnanavel Mutharasu, Reyka G. Jayasinghe, Song Cao, Wen-Wei Liao, et al. “Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.” Cell Rep 23, no. 1 (April 3, 2018): 227-238.e3. https://doi.org/10.1016/j.celrep.2018.03.050.
    Full Text Link to Item
  - Ge, Zhongqi, Jake S. Leighton, Yumeng Wang, Xinxin Peng, Zhongyuan Chen, Hu Chen, Yutong Sun, et al. “Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types.” Cell Rep 23, no. 1 (April 3, 2018): 213-226.e3. https://doi.org/10.1016/j.celrep.2018.03.047.
    Full Text Link to Item
  - Jayasinghe, Reyka G., Song Cao, Qingsong Gao, Michael C. Wendl, Nam Sy Vo, Sheila M. Reynolds, Yanyan Zhao, et al. “Systematic Analysis of Splice-Site-Creating Mutations in Cancer.” Cell Rep 23, no. 1 (April 3, 2018): 270-281.e3. https://doi.org/10.1016/j.celrep.2018.03.052.
    Full Text Link to Item
  - Knijnenburg, Theo A., Linghua Wang, Michael T. Zimmermann, Nyasha Chambwe, Galen F. Gao, Andrew D. Cherniack, Huihui Fan, et al. “Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.” Cell Rep 23, no. 1 (April 3, 2018): 239-254.e6. https://doi.org/10.1016/j.celrep.2018.03.076.
    Full Text Link to Item
  - Peng, Xinxin, Zhongyuan Chen, Farshad Farshidfar, Xiaoyan Xu, Philip L. Lorenzi, Yumeng Wang, Feixiong Cheng, et al. “Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers.” Cell Rep 23, no. 1 (April 3, 2018): 255-269.e4. https://doi.org/10.1016/j.celrep.2018.03.077.
    Full Text Link to Item
  - Ricketts, Christopher J., Aguirre A. De Cubas, Huihui Fan, Christof C. Smith, Martin Lang, Ed Reznik, Reanne Bowlby, et al. “The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma.” Cell Rep 23, no. 1 (April 3, 2018): 313-326.e5. https://doi.org/10.1016/j.celrep.2018.03.075.
    Full Text Link to Item
  - Saltz, Joel, Rajarsi Gupta, Le Hou, Tahsin Kurc, Pankaj Singh, Vu Nguyen, Dimitris Samaras, et al. “Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images.” Cell Rep 23, no. 1 (April 3, 2018): 181-193.e7. https://doi.org/10.1016/j.celrep.2018.03.086.
    Full Text Link to Item
  - Seiler, Michael, Shouyong Peng, Anant A. Agrawal, James Palacino, Teng Teng, Ping Zhu, Peter G. Smith, Peter G. Cancer Genome Atlas Research Network, Silvia Buonamici, and Lihua Yu. “Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types.” Cell Rep 23, no. 1 (April 3, 2018): 282-296.e4. https://doi.org/10.1016/j.celrep.2018.01.088.
    Full Text Link to Item
  - Way, Gregory P., Francisco Sanchez-Vega, Konnor La, Joshua Armenia, Walid K. Chatila, Augustin Luna, Chris Sander, et al. “Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas.” Cell Rep 23, no. 1 (April 3, 2018): 172-180.e3. https://doi.org/10.1016/j.celrep.2018.03.046.
    Full Text Link to Item
  - Ellrott, Kyle, Matthew H. Bailey, Gordon Saksena, Kyle R. Covington, Cyriac Kandoth, Chip Stewart, Julian Hess, et al. “Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines.” Cell Syst 6, no. 3 (March 28, 2018): 271-281.e7. https://doi.org/10.1016/j.cels.2018.03.002.
    Full Text Link to Item
  - Schaub, Franz X., Varsha Dhankani, Ashton C. Berger, Mihir Trivedi, Anne B. Richardson, Reid Shaw, Wei Zhao, et al. “Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.” Cell Syst 6, no. 3 (March 28, 2018): 282-300.e2. https://doi.org/10.1016/j.cels.2018.03.003.
    Full Text Link to Item
  - Foote, Jonathan, Micael Lopez-Acevedo, Gregory Samsa, Paula S. Lee, Arif H. Kamal, Angeles Alvarez Secord, and Laura J. Havrilesky. “Predicting 6- and 12-Month Risk of Mortality in Patients With Platinum-Resistant Advanced-Stage Ovarian Cancer: Prognostic Model to Guide Palliative Care Referrals.” Int J Gynecol Cancer 28, no. 2 (February 2018): 302–7. https://doi.org/10.1097/IGC.0000000000001182.
    Full Text Link to Item
  - Johnson, Omari K., Andrew Berchuck, Angeles A. Secord, and Andrew C. Peterson. “Urinary diversion in the genitourinary cancer survivor.” Gynecol Oncol 148, no. 2 (February 2018): 414–21. https://doi.org/10.1016/j.ygyno.2017.10.021.
    Full Text Link to Item
  - Richardson, Debra L., Michael W. Sill, Robert L. Coleman, Anil K. Sood, Michael L. Pearl, Siobhan M. Kehoe, Michael E. Carney, et al. “Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.” Jama Oncology 4, no. 2 (February 2018): 196–202. https://doi.org/10.1001/jamaoncol.2017.4218.
    Full Text
  - Dotson, Sarah, Alejandro Landa, Jessie Ehrisman, and Angeles Alvarez Secord. “Safety and feasibility of contained uterine morcellation in women undergoing laparoscopic hysterectomy.” Gynecol Oncol Res Pract 5 (2018): 8. https://doi.org/10.1186/s40661-018-0065-1.
    Full Text Link to Item
  - Berchuck, Andrew, Angeles Alvarez Secord, Haley A. Moss, and Laura J. Havrilesky. “Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?” J Clin Oncol 35, no. 36 (December 20, 2017): 3999–4002. https://doi.org/10.1200/JCO.2017.74.5752.
    Full Text Link to Item
  - Foote, Jonathan, Angeles Alvarez Secord, Margaret Liang, David E. Cohn, Elizabeth Jewell, and Laura J. Havrilesky. “ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer.” J Oncol Pract 13, no. 12 (December 2017): e1030–39. https://doi.org/10.1200/JOP.2017.025106.
    Full Text Link to Item
  - Tanner, Edward, Allison Puechl, Kimberly Levinson, Laura J. Havrilesky, Abdulrahman Sinno, Angeles Alvarez Secord, Amanda N. Fader, and Paula S. Lee. “Use of a novel sentinel lymph node mapping algorithm reduces the need for pelvic lymphadenectomy in low-grade endometrial cancer.” Gynecol Oncol 147, no. 3 (December 2017): 535–40. https://doi.org/10.1016/j.ygyno.2017.10.020.
    Full Text Link to Item
  - Oliver, Kate E., William E. Brady, Michael Birrer, David M. Gershenson, Gini Fleming, Larry J. Copeland, Krishnansu Tewari, et al. “An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience.” Gynecol Oncol 147, no. 2 (November 2017): 243–49. https://doi.org/10.1016/j.ygyno.2017.08.004.
    Full Text Link to Item
  - Phippen, N. T., A. A. Secord, S. Wolf, G. Samsa, B. Davidson, A. P. Abernethy, D. Cella, et al. “Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study.” Gynecol Oncol 147, no. 1 (October 2017): 98–103. https://doi.org/10.1016/j.ygyno.2017.07.121.
    Full Text Link to Item
  - Von Gruenigen, V. E., H. Q. Huang, J. H. Beumer, H. A. Lankes, W. Tew, T. Herzog, A. Hurria, et al. “Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/gynecologic oncology group study.” Obstetrical and Gynecological Survey 72, no. 8 (August 1, 2017): 481–82. https://doi.org/10.1097/01.ogx.0000524451.19814.73.
    Full Text
  - Winder, Abigail D., Kruti P. Maniar, Jian-Jun Wei, Dachao Liu, Denise M. Scholtens, John R. Lurain, Julian C. Schink, et al. “Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study.” Cancer 123, no. 7 (April 1, 2017): 1144–55. https://doi.org/10.1002/cncr.30477.
    Full Text Link to Item
  - Gruenigen, Vivian E. von, Helen Q. Huang, Jan H. Beumer, Heather A. Lankes, William Tew, Thomas Herzog, Arti Hurria, et al. “Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.” Gynecol Oncol 144, no. 3 (March 2017): 459–67. https://doi.org/10.1016/j.ygyno.2016.11.033.
    Full Text Link to Item
  - Pierce, Stuart R., Jessica E. Stine, Paola A. Gehrig, Laura J. Havrilesky, Angeles A. Secord, John Nakayama, Anna C. Snavely, Dominic T. Moore, and Kenneth H. Kim. “Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma.” Gynecol Oncol 144, no. 3 (March 2017): 531–35. https://doi.org/10.1016/j.ygyno.2016.12.024.
    Full Text Link to Item
  - Foote, Jonathan R., Micael Lopez-Acevedo, Adam H. Buchanan, Angeles Alvarez Secord, Paula S. Lee, Cynthia Fountain, Evan R. Myers, David E. Cohn, Shelby D. Reed, and Laura J. Havrilesky. “Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer.” J Oncol Pract 13, no. 2 (February 2017): e120–29. https://doi.org/10.1200/JOP.2016.011866.
    Full Text Link to Item
  - Foote, Jonathan R., Stephanie Gaillard, Gloria Broadwater, Julie A. Sosa, Brittany Davidson, Mohamed A. Adam, Angeles Alvarez Secord, Monica B. Jones, Junzo Chino, and Laura J. Havrilesky. “Disparities in the surgical staging of high-grade endometrial cancer in the United States.” Gynecol Oncol Res Pract 4 (2017): 1. https://doi.org/10.1186/s40661-016-0036-3.
    Full Text Open Access Copy Link to Item
  - Lee, Paula S., Samantha Kempner, Michael Miller, Jennifer Dominguez, Chad Grotegut, Jessie Ehrisman, Rebecca Previs, et al. “Multidisciplinary approach to manage antenatally suspected placenta percreta: updated algorithm and patient outcomes.” Gynecol Oncol Res Pract 4 (2017): 11. https://doi.org/10.1186/s40661-017-0049-6.
    Full Text Open Access Copy Link to Item
  - Garcia-Soto, Arlene E., James J. Java, Wilberto Nieves Neira, J Matthew Pearson, David E. Cohn, Shashikant B. Lele, Krishnansu S. Tewari, et al. “Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.” Gynecologic Oncology 143, no. 3 (December 2016): 484–89. https://doi.org/10.1016/j.ygyno.2016.10.003.
    Full Text
  - Dottino, Joseph A., Vic Hasselblad, Angeles Alvarez Secord, Evan R. Myers, Junzo Chino, and Laura J. Havrilesky. “Levonorgestrel Intrauterine Device as an Endometrial Cancer Prevention Strategy in Obese Women: A Cost-Effectiveness Analysis.” Obstet Gynecol 128, no. 4 (October 2016): 747–53. https://doi.org/10.1097/AOG.0000000000001616.
    Full Text Link to Item
  - Ehrisman, Jessie, Angeles Alvarez Secord, Andrew Berchuck, Paula S. Lee, Nicola Di Santo, Micael Lopez-Acevedo, Gloria Broadwater, Fidel A. Valea, and Laura J. Havrilesky. “Performance of sentinel lymph node biopsy in high-risk endometrial cancer.” Gynecol Oncol Rep 17 (August 2016): 69–71. https://doi.org/10.1016/j.gore.2016.04.002.
    Full Text Link to Item
  - Secord, Angeles Alvarez, and Laura J. Havrilesky. “Is Intraperitoneal Chemotherapy Dead?” Obstet Gynecol 127, no. 6 (June 2016): 983–84. https://doi.org/10.1097/AOG.0000000000001461.
    Full Text Link to Item
  - Davidson, Brittany A., Jonathan Foote, Stacey L. Brower, Chunqiao Tian, Laura J. Havrilesky, and Angeles Alvarez Secord. “Analysis of in vitro chemoresponse assays in endometrioid endometrial adenocarcinoma: an observational ancillary analysis.” Gynecol Oncol Res Pract 3 (2016): 13. https://doi.org/10.1186/s40661-016-0032-7.
    Full Text Open Access Copy Link to Item
  - Gaillard, Stéphanie L., Angeles A. Secord, and Bradley Monk. “The role of immune checkpoint inhibition in the treatment of ovarian cancer.” Gynecol Oncol Res Pract 3 (2016): 11. https://doi.org/10.1186/s40661-016-0033-6.
    Full Text Link to Item
  - Gray, H. J., B. Benigno, J. Berek, J. Chang, J. Mason, L. Mileshkin, P. Mitchell, et al. “Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial.” J Immunother Cancer 4 (2016): 34. https://doi.org/10.1186/s40425-016-0137-x.
    Full Text Open Access Copy Link to Item
  - Secord, Angeles Alvarez, Vic Hasselblad, Vivian E. Von Gruenigen, Paola A. Gehrig, Susan C. Modesitt, Victoria Bae-Jump, and Laura J. Havrilesky. “Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis.” Gynecol Oncol 140, no. 1 (January 2016): 184–90. https://doi.org/10.1016/j.ygyno.2015.10.020.
    Full Text Link to Item
  - Fuh, Katherine C., Angeles A. Secord, Kerri S. Bevis, Warner Huh, Adam ElNaggar, Kevin Blansit, Rebecca Previs, Todd Tillmanns, Daniel S. Kapp, and John K. Chan. “Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.” Gynecol Oncol 139, no. 3 (December 2015): 413–18. https://doi.org/10.1016/j.ygyno.2015.06.041.
    Full Text Link to Item
  - Fox, Karin A., Alireza A. Shamshirsaz, Daniela Carusi, Angeles Alvarez Secord, Paula Lee, Ozhan M. Turan, Christopher Huls, et al. “Conservative management of morbidly adherent placenta: expert review.” American Journal of Obstetrics and Gynecology 213, no. 6 (December 2015): 755–60. https://doi.org/10.1016/j.ajog.2015.04.034.
    Full Text
  - Dickson, Elizabeth L., Rachel Isaksson Vogel, Paola A. Gehrig, Stuart Pierce, Laura Havrilesky, Angeles Alvarez Secord, Joseph Dottino, Amanda N. Fader, Stephanie Ricci, and Melissa A. Geller. “A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.” Gynecol Oncol 139, no. 2 (November 2015): 275–82. https://doi.org/10.1016/j.ygyno.2015.09.002.
    Full Text Link to Item
  - Siamakpour-Reihani, Sharareh, Kouros Owzar, Chen Jiang, Taylor Turner, Yiwen Deng, Sarah M. Bean, Janet K. Horton, et al. “Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma.” Gynecol Oncol 139, no. 1 (October 2015): 23–29. https://doi.org/10.1016/j.ygyno.2015.08.001.
    Full Text Link to Item
  - Previs, Rebecca, Charles A. Leath, Robert L. Coleman, Thomas J. Herzog, Thomas C. Krivak, Stacey L. Brower, Chunqiao Tian, and Angeles Alvarez Secord. “Evaluation of in vitro chemoresponse profiles in women with Type I and Type II epithelial ovarian cancers: An observational study ancillary analysis.” Gynecol Oncol 138, no. 2 (August 2015): 267–71. https://doi.org/10.1016/j.ygyno.2015.05.038.
    Full Text Link to Item
  - Zhang, Chelsea, Dario Roque, Jessie A. Ehrisman, Nicola DiSanto, Gloria Broadwater, Kemi M. Doll, Paola A. Gehrig, Angeles Alvarez Secord, and Laura J. Havrilesky. “Lumbee Native American ancestry and the incidence of aggressive histologic subtypes of endometrial cancer.” Gynecol Oncol Rep 13 (August 2015): 49–52. https://doi.org/10.1016/j.gore.2015.06.004.
    Full Text Link to Item
  - Kushnir, C. L., A. M. Angarita, L. J. Havrilesky, S. Thompson, D. Spahlinger, A. K. Sinno, E. J. Tanner, et al. “Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD).” Gynecol Oncol 137, no. 3 (June 2015): 503–7. https://doi.org/10.1016/j.ygyno.2015.02.020.
    Full Text Link to Item
  - Secord, Angeles A., Robert L. Coleman, Laura J. Havrilesky, Amy P. Abernethy, Gregory P. Samsa, and David Cella. “Patient-reported outcomes as end points and outcome indicators in solid tumours.” Nat Rev Clin Oncol 12, no. 6 (June 2015): 358–70. https://doi.org/10.1038/nrclinonc.2015.29.
    Full Text Link to Item
  - Cobb, Lauren Patterson, Stephanie Gaillard, Yihong Wang, Ie-Ming Shih, and Angeles Alvarez Secord. “Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms.” Gynecol Oncol Res Pract 2 (2015): 1. https://doi.org/10.1186/s40661-015-0008-z.
    Full Text Link to Item
  - Havrilesky, Laura J., Angeles Alvarez Secord, Jessie A. Ehrisman, Andrew Berchuck, Fidel A. Valea, Paula S. Lee, Stephanie L. Gaillard, et al. “Patient preferences in advanced or recurrent ovarian cancer.” Cancer 120, no. 23 (December 1, 2014): 3651–59. https://doi.org/10.1002/cncr.28940.
    Full Text Link to Item
  - Secord, Angeles Alvarez, Andrew B. Nixon, and Herbert I. Hurwitz. “The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer.” Gynecol Oncol 135, no. 2 (November 2014): 349–58. https://doi.org/10.1016/j.ygyno.2014.08.033.
    Full Text Link to Item
  - Kokosis, G., R. Schmitz, A. A. Secord, L. J. Havrilesky, A. Berchuck, C. R. Mantyh, and D. Erdmann. “A modified bipedicle VRAM flap for simultaneous reconstruction of a perineal and posterior vaginal defect.” Gynakologe 47, no. 10 (October 14, 2014): 784–87. https://doi.org/10.1007/s00129-014-3448-3.
    Full Text
  - Herzog, Thomas J., Ronald D. Alvarez, Angeles Secord, Barbara A. Goff, Robert S. Mannel, Bradley J. Monk, and Robert L. Coleman. “SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm.” Gynecol Oncol 135, no. 1 (October 2014): 3–7. https://doi.org/10.1016/j.ygyno.2014.08.004.
    Full Text Link to Item
  - Krivak, Thomas C., Shashikant Lele, Scott Richard, Angeles Alvarez Secord, Charles A. Leath, Stacey L. Brower, Chunqiao Tian, and Richard G. Moore. “A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.” American Journal of Obstetrics and Gynecology 211, no. 1 (July 2014): 68.e1-68.e8. https://doi.org/10.1016/j.ajog.2014.02.009.
    Full Text
  - Previs, Rebecca Ann, Joshua Kilgore, Renatta Craven, Gloria Broadwater, Sarah Bean, Sara Wobker, Megan DiFurio, Victoria Bae-Jump, Paola A. Gehrig, and Angeles Alvarez Secord. “Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancer.” Int J Gynecol Cancer 24, no. 4 (May 2014): 670–75. https://doi.org/10.1097/IGC.0000000000000109.
    Full Text Link to Item
  - Zhang, Chelsea, Laura J. Havrilesky, Gloria Broadwater, Nicola Di Santo, Jessie A. Ehrisman, Paula S. Lee, Andrew Berchuck, et al. “Relationship between minimally invasive hysterectomy, pelvic cytology, and lymph vascular space invasion: a single institution study of 458 patients.” Gynecol Oncol 133, no. 2 (May 2014): 211–15. https://doi.org/10.1016/j.ygyno.2014.02.025.
    Full Text Link to Item
  - Lee, Paula S., and Angeles Alvarez Secord. “Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway.” Cancer Treat Rev 40, no. 4 (May 2014): 507–12. https://doi.org/10.1016/j.ctrv.2013.11.004.
    Full Text Link to Item
  - Ko, Emily M., Paige Walter, Leslie Clark, Amanda Jackson, Jason Franasiak, Corey Bolac, Laura Havrilesky, et al. “The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance.” Gynecol Oncol 133, no. 1 (April 2014): 28–32. https://doi.org/10.1016/j.ygyno.2014.01.032.
    Full Text Link to Item
  - Herzog, Thomas J., Bradley J. Monk, Peter G. Rose, Patricia Braly, Jeffrey F. Hines, Maria C. Bell, Robert M. Wenham, et al. “A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.” Gynecol Oncol 132, no. 3 (March 2014): 517–25. https://doi.org/10.1016/j.ygyno.2014.01.035.
    Full Text Link to Item
  - Previs, R. A., K. S. Bevis, W. Huh, T. Tillmanns, L. Perry, K. Moore, J. Chapman, et al. “A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.” Gynecol Oncol 132, no. 3 (March 2014): 531–36. https://doi.org/10.1016/j.ygyno.2014.01.036.
    Full Text Link to Item
  - Ko, Emily M., Paige Walter, Amanda Jackson, Leslie Clark, Jason Franasiak, Corey Bolac, Laura J. Havrilesky, et al. “Metformin is associated with improved survival in endometrial cancer.” Gynecol Oncol 132, no. 2 (February 2014): 438–42. https://doi.org/10.1016/j.ygyno.2013.11.021.
    Full Text Link to Item
  - Secord, Angeles Alvarez, Deanna Teoh, Jingquan Jia, Andrew B. Nixon, Lisa Grace, David J. Adams, and Susan K. Murphy. “Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.” Int J Gynecol Cancer 24, no. 2 (February 2014): 218–25. https://doi.org/10.1097/IGC.0000000000000056.
    Full Text Link to Item
  - Davidson, Brittany A., and Angeles Alvarez Secord. “Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer.” Int J Womens Health 6 (2014): 289–300. https://doi.org/10.2147/IJWH.S49781.
    Full Text Open Access Copy Link to Item
  - Davidson, Brittany Anne, Jennifer M. Rubatt, David L. Corcoran, Deanna K. Teoh, Marcus Q. Bernardini, Lisa A. Grace, William John Soper, et al. “Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines.” Front Oncol 4 (2014): 163. https://doi.org/10.3389/fonc.2014.00163.
    Full Text Link to Item
  - Lee, P. S., and A. A. Secord. “Targeting molecular pathways in endometrial cancer: A focus on the FGFR pathway.” Cancer Treatment Reviews 40, no. 4 (2014): 507–12.
  - Lopez-Acevedo, Micael, Lisa Grace, Deanna Teoh, Regina Whitaker, David J. Adams, Jingquan Jia, Andrew B. Nixon, and Angeles Alvarez Secord. “Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines.” Gynecol Oncol Res Pract 1 (2014): 2. https://doi.org/10.1186/2053-6844-1-2.
    Full Text Open Access Copy Link to Item
  - Previs, Rebecca A., James M. Edwards, Angeles A. Secord, Marisa R. Nucci, Rex C. Bentley, and Allison H. S. Hall. “Cystic fibrosis involving the cervix, mimicking a well-differentiated adenocarcinoma: a case report.” Int J Gynecol Pathol 33, no. 1 (January 2014): 100–104. https://doi.org/10.1097/PGP.0b013e318278b832.
    Full Text Link to Item
  - Ricci, Stephanie, Robert L. Giuntoli, Eric Eisenhauer, Micael A. Lopez, Lauren Krill, Edward J. Tanner, Paola A. Gehrig, et al. “Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?” Gynecol Oncol 131, no. 3 (December 2013): 629–33. https://doi.org/10.1016/j.ygyno.2013.08.037.
    Full Text Link to Item
  - Barnett, Jason C., Angeles Alvarez Secord, David E. Cohn, Charles A. Leath, Evan R. Myers, and Laura J. Havrilesky. “Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.” Cancer 119, no. 20 (October 15, 2013): 3653–61. https://doi.org/10.1002/cncr.28283.
    Full Text Link to Item
  - Karabudak, Aykan A., Julie Hafner, Vivekananda Shetty, Songming Chen, Angeles Alvarez Secord, Michael A. Morse, and Ramila Philip. “Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.” J Cancer Res Clin Oncol 139, no. 10 (October 2013): 1757–70. https://doi.org/10.1007/s00432-013-1501-6.
    Full Text Link to Item
  - Krivak, T., A Alvarez Secord, S. Richard, C. Leath, R. Moore, R. Coleman, J. Fiorica, et al. “A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.” Gynecologic Oncology 131, no. 1 (October 2013): 276–276. https://doi.org/10.1016/j.ygyno.2013.07.076.
    Full Text
  - Lowery, William J., Ashlei W. Lowery, Jason C. Barnett, Micael Lopez-Acevedo, Paula S. Lee, Angeles Alvarez Secord, and Laura Havrilesky. “Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer.” Gynecol Oncol 130, no. 3 (September 2013): 426–30. https://doi.org/10.1016/j.ygyno.2013.06.011.
    Full Text Link to Item
  - Chino, Junzo, and Angeles Alvarez Secord. “Image-guided brachytherapy for gynecologic surgeons.” Surg Oncol Clin N Am 22, no. 3 (July 2013): 495–509. https://doi.org/10.1016/j.soc.2013.02.002.
    Full Text Link to Item
  - Lopez-Acevedo, Micael, Laura J. Havrilesky, Gloria Broadwater, Arif H. Kamal, Amy P. Abernethy, Andrew Berchuck, Angeles Alvarez Secord, James A. Tulsky, Fidel Valea, and Paula S. Lee. “Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancer.” Gynecol Oncol 130, no. 1 (July 2013): 156–61. https://doi.org/10.1016/j.ygyno.2013.04.010.
    Full Text Link to Item
  - Wenham, Robert M., James Lapolla, Hui-Yi Lin, Sachin M. Apte, Johnathan M. Lancaster, Patricia L. Judson, Jesus Gonzalez-Bosquet, Amber Herschberger, Laura J. Havrilesky, and Angeles Alvarez Secord. “A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy.” Gynecol Oncol 130, no. 1 (July 2013): 19–24. https://doi.org/10.1016/j.ygyno.2013.04.049.
    Full Text Link to Item
  - Zighelboim, Israel, Jason D. Wright, Feng Gao, Ashley S. Case, L Stewart Massad, David G. Mutch, Matthew A. Powell, et al. “Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.” Gynecol Oncol 130, no. 1 (July 2013): 64–68. https://doi.org/10.1016/j.ygyno.2013.04.009.
    Full Text Link to Item
  - Secord, Angeles Alvarez, Jason Cory Barnett, Jonathan A. Ledermann, Bercedis L. Peterson, Evan R. Myers, and Laura J. Havrilesky. “Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.” Int J Gynecol Cancer 23, no. 5 (June 2013): 846–52. https://doi.org/10.1097/IGC.0b013e31829527bd.
    Full Text Link to Item
  - Alvarez Secord, Angeles, and Christine S. Walsh. “Summary of the 44th Annual Meeting on Women's Cancers.” Gynecol Oncol 129, no. 2 (May 2013): 273–76. https://doi.org/10.1016/j.ygyno.2013.03.028.
    Full Text Link to Item
  - Hanna, Rabbie K., Marek S. Poniewierski, Robin A. Laskey, Micael A. Lopez, Aaron Shafer, Linda Van Le, Jeffrey Crawford, et al. “Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer.” Gynecol Oncol 129, no. 1 (April 2013): 74–80. https://doi.org/10.1016/j.ygyno.2012.12.017.
    Full Text Link to Item
  - Alvarez Secord, Angeles, Marcus Q. Bernardini, Gloria Broadwater, Lisa A. Grace, Zhiqing Huang, Tsukasa Baba, Eiji Kondoh, Gregory Sfakianos, Laura J. Havrilesky, and Susan K. Murphy. “TP53 Status is Associated with Thrombospondin1 Expression In vitro.” Front Oncol 3 (2013): 269. https://doi.org/10.3389/fonc.2013.00269.
    Full Text Link to Item
  - Garg, Karuna, Douglas A. Levine, Narciso Olvera, Fanny Dao, Maria Bisogna, Angeles Alvarez Secord, Andrew Berchuck, Ethan Cerami, Nikolaus Schultz, and Robert A. Soslow. “BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.” Am J Surg Pathol 37, no. 1 (January 2013): 138–46. https://doi.org/10.1097/PAS.0b013e31826cabbd.
    Full Text Link to Item
  - Secord, Angeles Alvarez, Melissa A. Geller, Gloria Broadwater, Robert Holloway, Kevin Shuler, Nhu-Y Dao, Paola A. Gehrig, David M. O’Malley, Neil Finkler, and Laura J. Havrilesky. “A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer.” Gynecol Oncol 128, no. 1 (January 2013): 65–70. https://doi.org/10.1016/j.ygyno.2012.10.010.
    Full Text Link to Item
  - Turner, Taylor, Angeles Alvarez Secord, William J. Lowery, Gregory Sfakianos, and Paula S. Lee. “Metastatic adenocarcinoma after laparoscopic supracervical hysterectomy with morcellation: A case report.” Gynecol Oncol Case Rep 5 (2013): 19–21. https://doi.org/10.1016/j.gynor.2013.03.002.
    Full Text Link to Item
  - Lopez-Acevedo, Micael, Chelsea Zhang, Angeles Alvarez Secord, Paula S. Lee, Laura Jean Havrilesky, and Andrew Berchuck. “Predictors of failure to perform pelvic peritoneal cytology in endometrial cancer staging surgery.” Journal of Clinical Oncology 30, no. 34 (December 1, 2012). https://doi.org/10.1200/jco.2012.30.34_suppl.201.
    Full Text Link to Item
  - Zhang, C., A. A. Secord, P. S. Lee, L. J. Havrilesky, and A. Berchuck. “Predictors of failure to perform pelvic peritoneal cytology in endometrial cancer staging surgery.” J Clin Oncol 30, no. 34_suppl (December 2012): 201. https://doi.org/10.1200/jco.2012.30.34_suppl.201.
    Full Text Link to Item
  - Lowery, W. J., P. A. Gehrig, E. Ko, A. A. Secord, J. Chino, and L. J. Havrilesky. “Surgical staging for endometrial cancer in the elderly - Is there a role for lymphadenectomy?” Obstetrical and Gynecological Survey 67, no. 11 (November 1, 2012): 702–3. https://doi.org/10.1097/OGX.0b013e31827681f1.
    Full Text
  - Cantrell, Leigh A., Laura Havrilesky, Dominic T. Moore, David O’Malley, Margaret Liotta, Angeles Alvarez Secord, Christa I. Nagel, et al. “A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma.” Gynecol Oncol 127, no. 1 (October 2012): 22–26. https://doi.org/10.1016/j.ygyno.2012.06.020.
    Full Text Link to Item
  - Secord, Angeles Alvarez, Deanna K. Teoh, William T. Barry, Miao Yu, Gloria Broadwater, Laura J. Havrilesky, Paula S. Lee, Andrew Berchuck, Johnathan Lancaster, and Robert M. Wenham. “A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.” Clin Cancer Res 18, no. 19 (October 1, 2012): 5489–98. https://doi.org/10.1158/1078-0432.CCR-12-0507.
    Full Text Link to Item
  - Franasiak, Jason, Emily M. Ko, Juli Kidd, Angeles Alvarez Secord, Maria Bell, John F. Boggess, and Paola A. Gehrig. “Physical strain and urgent need for ergonomic training among gynecologic oncologists who perform minimally invasive surgery.” Gynecol Oncol 126, no. 3 (September 2012): 437–42. https://doi.org/10.1016/j.ygyno.2012.05.016.
    Full Text Link to Item
  - Aghajanian, Carol, Michael W. Sill, Angeles Alvarez Secord, Matthew A. Powell, and Margaret Steinhoff. “Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study.” Gynecol Oncol 126, no. 3 (September 2012): 424–27. https://doi.org/10.1016/j.ygyno.2012.05.024.
    Full Text Link to Item
  - Fader, Amanda Nickles, Leigh G. Seamon, Pedro F. Escobar, Heidi E. Frasure, Laura A. Havrilesky, Kristine M. Zanotti, Angeles Alvarez Secord, et al. “Minimally invasive surgery versus laparotomy in women with high grade endometrial cancer: a multi-site study performed at high volume cancer centers.” Gynecol Oncol 126, no. 2 (August 2012): 180–85. https://doi.org/10.1016/j.ygyno.2012.04.028.
    Full Text Link to Item
  - Secord, Angeles Alvarez, and Paola A. Gehrig. “Obesity: Too big a problem to ignore.” Gynecol Oncol 126, no. 2 (August 2012): 274–76. https://doi.org/10.1016/j.ygyno.2012.04.033.
    Full Text Link to Item
  - Alvarez Secord, Angeles, Andrew Berchuck, Robert V. Higgins, Lawrence R. Nycum, Matthew F. Kohler, Larry E. Puls, Robert W. Holloway, George S. Lewandowski, Fidel A. Valea, and Laura J. Havrilesky. “A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.” Cancer 118, no. 13 (July 1, 2012): 3283–93. https://doi.org/10.1002/cncr.26610.
    Full Text Link to Item
  - Edwards, James M., William Jeffrey Lowery, and Angeles Alvarez Secord. “Quinary debulking for epithelial ovarian cancer.” J Surg Case Rep 2012, no. 7 (July 1, 2012): 7. https://doi.org/10.1093/jscr/2012.7.7.
    Full Text Link to Item
  - Lowery, William J., Paola A. Gehrig, Emily Ko, Angeles Alvarez Secord, Junzo Chino, and Laura J. Havrilesky. “Surgical staging for endometrial cancer in the elderly - is there a role for lymphadenectomy?” Gynecol Oncol 126, no. 1 (July 2012): 12–15. https://doi.org/10.1016/j.ygyno.2012.05.003.
    Full Text Link to Item
  - Vlahovic, Gordana, Kellen L. Meadows, Hope E. Uronis, Michael A. Morse, Gerard C. Blobe, Richard F. Riedel, S Yousuf Zafar, et al. “A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.” Cancer Chemother Pharmacol 70, no. 1 (July 2012): 95–102. https://doi.org/10.1007/s00280-012-1889-8.
    Full Text Link to Item
  - Laskey, Robin A., Marek S. Poniewierski, Micael A. Lopez, Rabbie K. Hanna, Angeles Alvarez Secord, Paola A. Gehrig, Gary H. Lyman, and Laura J. Havrilesky. “Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer.” Gynecol Oncol 125, no. 3 (June 2012): 625–30. https://doi.org/10.1016/j.ygyno.2012.03.015.
    Full Text Link to Item
  - Chino, Junzo P., Ellen Jones, Andrew Berchuck, Angeles Alvarez Secord, and Laura J. Havrilesky. “The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer.” Int J Radiat Oncol Biol Phys 82, no. 5 (April 1, 2012): 1872–79. https://doi.org/10.1016/j.ijrobp.2011.03.054.
    Full Text Link to Item
  - Berchuck, Andrew, Angeles Alvarez Secord, and Laura J. Havrilesky. “Minimally invasive surgery for endometrial cancer: the horse is already out of the barn.” J Clin Oncol 30, no. 7 (March 1, 2012): 681–82. https://doi.org/10.1200/JCO.2011.40.5506.
    Full Text Link to Item
  - Teoh, Deanna, and Angeles Alvarez Secord. “Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.” Int J Gynecol Cancer 22, no. 3 (March 2012): 348–59. https://doi.org/10.1097/IGC.0b013e31823c6efd.
    Full Text Link to Item
  - Havrilesky, Laura J., Robin Pokrzywinski, Dennis Revicki, Robert V. Higgins, Lawrence R. Nycum, Matthew F. Kohler, Andrew Berchuck, Evan R. Myers, and Angeles Alvarez Secord. “Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.” Cancer 118, no. 2 (January 15, 2012): 386–91. https://doi.org/10.1002/cncr.26199.
    Full Text Link to Item
  - Pokrzywinski, Robin, Angeles Alvarez Secord, Laura J. Havrilesky, Larry E. Puls, Robert W. Holloway, George S. Lewandowski, Robert V. Higgins, Lawrence R. Nycum, Matthew F. Kohler, and Dennis A. Revicki. “Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial.” Gynecol Oncol 123, no. 3 (December 2011): 505–10. https://doi.org/10.1016/j.ygyno.2011.08.015.
    Full Text Link to Item
  - Alvarez Secord, Angeles, Kathleen M. Darcy, Alan Hutson, Zhiqing Huang, Paula S. Lee, Elizabeth L. Jewell, Laura J. Havrilesky, Maurie Markman, Franco Muggia, and Susan K. Murphy. “The regulation of MASPIN expression in epithelial ovarian cancer: association with p53 status, and MASPIN promoter methylation: a gynecologic oncology group study.” Gynecol Oncol 123, no. 2 (November 2011): 314–19. https://doi.org/10.1016/j.ygyno.2011.08.003.
    Full Text Link to Item
  - Convery, Patricia A., Leigh A. Cantrell, Nicola Di Santo, Gloria Broadwater, Susan C. Modesitt, Angeles Alvarez Secord, and Laura J. Havrilesky. “Retrospective review of an intraoperative algorithm to predict lymph node metastasis in low-grade endometrial adenocarcinoma.” Gynecol Oncol 123, no. 1 (October 2011): 65–70. https://doi.org/10.1016/j.ygyno.2011.06.025.
    Full Text Link to Item
  - Teoh, Deanna, Andrew Berchuck, Angeles Alvarez Secord, Paula S. Lee, William J. Lowery, Gregory P. Sfakianos, Fidel A. Valea, Evan R. Myers, and Laura J. Havrilesky. “Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer.” Gynecol Oncol 122, no. 3 (September 2011): 467–72. https://doi.org/10.1016/j.ygyno.2011.06.014.
    Full Text Link to Item
  - Barnett, Jason C., Laura J. Havrilesky, Amy E. Bondurant, Nicole D. Fleming, Paula S. Lee, Angeles Alvarez Secord, Andrew Berchuck, and Fidel A. Valea. “Adverse events associated with laparoscopy vs laparotomy in the treatment of endometrial cancer.” Am J Obstet Gynecol 205, no. 2 (August 2011): 143.e1-143.e6. https://doi.org/10.1016/j.ajog.2011.03.012.
    Full Text Link to Item
  - Havrilesky, L. J., R. K. Hanna, M. S. Poniewierski, R. Laskey, A. A. Secord, P. A. Gehrig, M. A. Lopez, et al. “Relationship between relative dose intensity and mortality in women receiving combination chemotherapy for stage III-IV epithelial ovarian cancer.” J Clin Oncol 29, no. 15_suppl (May 20, 2011): 5084.
    Link to Item
  - Morse, Michael A., Angeles A. Secord, Kimberly Blackwell, Amy C. Hobeika, Gomathinayagam Sinnathamby, Takuya Osada, Julie Hafner, et al. “MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer.” Clin Cancer Res 17, no. 10 (May 15, 2011): 3408–19. https://doi.org/10.1158/1078-0432.CCR-10-2614.
    Full Text Link to Item
  - Teoh, Deanna, Tina A. Ayeni, Jennifer M. Rubatt, David J. Adams, Lisa Grace, Mark D. Starr, William T. Barry, Andrew Berchuck, Susan K. Murphy, and Angeles Alvarez Secord. “Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.” Gynecol Oncol 121, no. 1 (April 2011): 187–92. https://doi.org/10.1016/j.ygyno.2010.11.017.
    Full Text Link to Item
  - Osborne, Raymond J., Virginia Filiaci, Julian C. Schink, Robert S. Mannel, Angeles Alvarez Secord, Joseph L. Kelley, Diane Provencher, David Scott Miller, Allan L. Covens, and Janice M. Lage. “Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study.” J Clin Oncol 29, no. 7 (March 1, 2011): 825–31. https://doi.org/10.1200/JCO.2010.30.4386.
    Full Text Link to Item
  - Sinnathamby, G., J. Zerfass, J. Hafner, P. Block, Z. Nickens, A. Hobeika, A. A. Secord, H. K. Lyerly, M. A. Morse, and R. Philip. “ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.” Clinical and Experimental Immunology 163, no. 3 (March 2011): 324–32. https://doi.org/10.1111/j.1365-2249.2010.04298.x.
    Full Text
  - Teoh, Deanna G. K., and Angeles Alvarez Secord. “Antiangiogenic therapies in epithelial ovarian cancer.” Cancer Control 18, no. 1 (January 2011): 31–43. https://doi.org/10.1177/107327481101800105.
    Full Text Link to Item
  - Teoh, Deanna, John S. Won, Robert Eisberg, Kimberly Nolte, and Angeles Alvarez Secord. “Severe ulceration over mandibular torus in an ovarian cancer patient receiving bevacizumab therapy.” Gynecol Oncol Case Rep 1, no. 1 (2011): 20–21. https://doi.org/10.1016/j.gynor.2011.09.001.
    Full Text Link to Item
  - Zani, Sabino, Maggie Stoecker, Mitchell W. Cox, Angeles Alvarez Secord, and Dan G. Blazer. “Recurrent granulosa cell tumor presenting with spontaneous retroperitoneal hemorrhage: A case report.” Gynecol Oncol Case Rep 1, no. 1 (2011): 14–16. https://doi.org/10.1016/j.gynor.2011.09.003.
    Full Text Link to Item
  - Miller, Brigitte E., John A. Blessing, Frederick B. Stehman, Mark S. Shahin, S Diane Yamada, Angeles Alvarez Secord, David P. Warshal, Ovadia Abulafia, William E. Richards, and Linda Van Le. “A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study.” Gynecol Oncol 118, no. 2 (August 1, 2010): 139–44. https://doi.org/10.1016/j.ygyno.2010.03.024.
    Full Text Link to Item
  - Bernardini, Marcus Q., Tsukasa Baba, Paula S. Lee, Jason C. Barnett, Gregory P. Sfakianos, Angeles Alvarez Secord, Susan K. Murphy, Edwin Iversen, Jeffrey R. Marks, and Andrew Berchuck. “Expression signatures of TP53 mutations in serous ovarian cancers.” Bmc Cancer 10 (May 26, 2010): 237. https://doi.org/10.1186/1471-2407-10-237.
    Full Text Open Access Copy Link to Item
  - Zighelboim, I., J. D. Wright, M. A. Powell, A. S. Case, E. L. Eisenhauer, D. E. Cohn, F. A. Valea, A. A. Secord, L. T. Lippmann, and J. S. Rader. “Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancer.” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): TPS252–TPS252. https://doi.org/10.1200/jco.2010.28.15_suppl.tps252.
    Full Text
  - Lee, Paula S., Vanessa S. Teaberry, Amy E. Bland, Zhiqing Huang, Regina S. Whitaker, Tsukasa Baba, Shingo Fujii, Angeles Alvarez Secord, Andrew Berchuck, and Susan K. Murphy. “Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.” Int J Cancer 126, no. 6 (March 15, 2010): 1378–89. https://doi.org/10.1002/ijc.24797.
    Full Text Link to Item
  - Rasool, Nabila, Amanda Nickles Fader, Leigh Seamon, Nikki L. Neubauer, Fadi Abu Shahin, Heather A. Alexander, Kathleen Moore, et al. “Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence.” Gynecol Oncol 116, no. 1 (January 2010): 10–14. https://doi.org/10.1016/j.ygyno.2009.10.043.
    Full Text Link to Item
  - Jewell, Elizabeth L., Kathleen M. Darcy, Alan Hutson, Paula S. Lee, Laura J. Havrilesky, Lisa A. Grace, Andrew Berchuck, and Angeles Alvarez Secord. “Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study.” Gynecol Oncol 115, no. 3 (December 2009): 424–29. https://doi.org/10.1016/j.ygyno.2009.07.035.
    Full Text Link to Item
  - Fader, Amanda Nickles, David Starks, Paola A. Gehrig, Angeles Alvarez Secord, Heidi E. Frasure, David M. O’Malley, Erin R. Tuller, et al. “An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).” Gynecol Oncol 115, no. 2 (November 2009): 244–48. https://doi.org/10.1016/j.ygyno.2009.07.030.
    Full Text Link to Item
  - Fiorica, James V., John A. Blessing, Louis V. Puneky, Angeles Alvarez Secord, James S. Hoffman, S Diane Yamada, Thomas E. Buekers, Jeffrey Bell, Jeanne M. Schilder, and Jeanne M. Gynecologic Oncology Group. “A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study.” Gynecol Oncol 115, no. 2 (November 2009): 285–89. https://doi.org/10.1016/j.ygyno.2009.07.024.
    Full Text Link to Item
  - Secord, A. A., and N. L. Neubauer. “In response to "The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma".” Gynecologic Oncology 115, no. 2 (November 1, 2009): 317. https://doi.org/10.1016/j.ygyno.2009.07.012.
    Full Text
  - Lee, Paula S., Amy Bland, Fidel A. Valea, Laura J. Havrilesky, Andrew Berchuck, and Angeles Alvarez Secord. “Robotic-assisted laparoscopic gynecologic procedures in a fellowship training program.” Jsls 13, no. 4 (October 2009): 467–72. https://doi.org/10.4293/108680809X12589998403921.
    Full Text Link to Item
  - Sinnathamby, Gomathinayagam, Peter Lauer, Jennifer Zerfass, Bill Hanson, Aykan Karabudak, Jonathan Krakover, Angeles Alvarez Secord, et al. “Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines.” J Immunother 32, no. 8 (October 2009): 856–69. https://doi.org/10.1097/CJI.0b013e3181b0b125.
    Full Text Link to Item
  - Fleming, Nicole D., Angeles Alvarez-Secord, Vivian Von Gruenigen, Michael J. Miller, and Amy P. Abernethy. “Indwelling catheters for the management of refractory malignant ascites: a systematic literature overview and retrospective chart review.” J Pain Symptom Manage 38, no. 3 (September 2009): 341–49. https://doi.org/10.1016/j.jpainsymman.2008.09.008.
    Full Text Link to Item
  - Secord, Angeles Alvarez, Laura J. Havrilesky, David M. O’Malley, Victoria Bae-Jump, Nicole D. Fleming, Gloria Broadwater, David E. Cohn, and Paola A. Gehrig. “A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer.” Gynecol Oncol 114, no. 3 (September 2009): 442–47. https://doi.org/10.1016/j.ygyno.2009.06.005.
    Full Text Link to Item
  - Havrilesky, Laura J., Angeles Alvarez Secord, David M. O’Malley, Gloria Broadwater, Victoria Bae-Jump, David E. Cohn, and Paola A. Gehrig. “Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer.” Gynecol Oncol 114, no. 2 (August 2009): 279–83. https://doi.org/10.1016/j.ygyno.2009.04.030.
    Full Text Link to Item
  - Cantrell, L. A., L. Havrilesky, D. O’Malley, M. Liotta, A. A. Secord, C. Nagel, A. N. Fader, A. Wallace, P. Rose, and P. A. Gehrig. “Effect of treatment of patients with early-stage uterine carcinosarcoma.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 5516.
    Link to Item
  - Greer, Benjamin E., Wui-Jin Koh, Nadeem Abu-Rustum, Michael A. Bookman, Robert E. Bristow, Susana M. Campos, Kathleen R. Cho, et al. “Uterine Neoplasms. Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 7, no. 5 (May 2009): 498–531. https://doi.org/10.6004/jnccn.2009.0035.
    Full Text Link to Item
  - Alvarez Secord, Angeles, Victoria Bae-Jump, Laura J. Havrilesky, Brian Calingaert, Daniel L. Clarke-Pearson, John T. Soper, and Paola A. Gehrig. “Attitudes regarding the use of hematopoietic colony-stimulating factors and maintenance of relative dose intensity among gynecologic oncologists.” Int J Gynecol Cancer 19, no. 3 (April 2009): 447–54. https://doi.org/10.1111/IGC.0b013e3181a1a6c9.
    Full Text Link to Item
  - Berchuck, Andrew, Edwin S. Iversen, Jingqin Luo, Jennifer P. Clarke, Hisani Horne, Douglas A. Levine, Jeff Boyd, et al. “Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome.” Clin Cancer Res 15, no. 7 (April 1, 2009): 2448–55. https://doi.org/10.1158/1078-0432.CCR-08-2430.
    Full Text Link to Item
  - Fader, Amanda Nickles, Christa Nagel, Allison E. Axtell, Kristine M. Zanotti, Joseph L. Kelley, Kathleen N. Moore, Angeles Alvarez Secord, et al. “Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.” Gynecol Oncol 112, no. 3 (March 2009): 558–62. https://doi.org/10.1016/j.ygyno.2008.11.016.
    Full Text Link to Item
  - Neubauer, Nikki L., Laura J. Havrilesky, Brian Calingaert, Anuradha Bulusu, Marcus Q. Bernardini, Nicole D. Fleming, Amy E. Bland, and Angeles Alvarez Secord. “The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma.” Gynecol Oncol 112, no. 3 (March 2009): 511–16. https://doi.org/10.1016/j.ygyno.2008.11.012.
    Full Text Link to Item
  - Rubatt, Jennifer M., Kathleen M. Darcy, Alan Hutson, Sarah M. Bean, Laura J. Havrilesky, Lisa A. Grace, Andrew Berchuck, and Angeles Alvarez Secord. “Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.” Gynecol Oncol 112, no. 3 (March 2009): 469–74. https://doi.org/10.1016/j.ygyno.2008.11.030.
    Full Text Link to Item
  - Resnick, K. E., H. Alder, A Alvarez Secord, R. Whitaker, D. L. Richardson, C. Heaphy, S. K. Murphy, T. Baba, C. Croce, and D. E. Colin. “MiRNA patterns in ovarian cancer cell lines: Correlation with serum studies.” Gynecologic Oncology 112, no. 2 (February 1, 2009): S115–16.
    Link to Item
  - Bland, Amy E., Brian Calingaert, Angeles Alvarez Secord, Paula S. Lee, Fidel A. Valea, Andrew Berchuck, John T. Soper, and Laura Havrilesky. “Relationship between tamoxifen use and high risk endometrial cancer histologic types.” Gynecol Oncol 112, no. 1 (January 2009): 150–54. https://doi.org/10.1016/j.ygyno.2008.08.035.
    Full Text Link to Item
  - Sabbatini, Paul, Michael W. Sill, David O’Malley, Lisa Adler, Angeles Alvarez Secord, and Angeles Alvarez Gynecologic Oncology Group Study. “A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.” Gynecol Oncol 111, no. 3 (December 2008): 455–60. https://doi.org/10.1016/j.ygyno.2008.07.049.
    Full Text Link to Item
  - Havrilesky, Laura J., Angeles Alvarez Secord, Kathleen M. Darcy, Deborah K. Armstrong, Shalini Kulasingam, and Shalini Gynecologic Oncology Group. “Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.” J Clin Oncol 26, no. 25 (September 1, 2008): 4144–50. https://doi.org/10.1200/JCO.2007.13.1961.
    Full Text Link to Item
  - Lee, Paula S., Ryan Bakelaar, C Brennan Fitpatrick, Sarah C. Ellestad, Laura J. Havrilesky, and Angeles Alvarez Secord. “Medical and surgical treatment of placenta percreta to optimize bladder preservation.” Obstet Gynecol 112, no. 2 Pt 2 (August 2008): 421–24. https://doi.org/10.1097/AOG.0b013e31817e7966.
    Full Text Link to Item
  - Bland, A. E., A. A. Shah, J. T. Piscitelli, R. C. Bentley, and A. A. Secord. “Desmoplastic small round cell tumor masquerading as advanced ovarian cancer.” Int J Gynecol Cancer 18, no. 4 (July 2008): 847–50. https://doi.org/10.1111/j.1525-1438.2007.01110.x.
    Full Text Link to Item
  - Wright, J. D., A. A. Secord, T. M. Numnum, R. P. Rocconi, M. A. Powell, A. Berchuck, R. D. Alvarez, et al. “A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer.” Int J Gynecol Cancer 18, no. 3 (May 2008): 400–406. https://doi.org/10.1111/j.1525-1438.2007.01027.x.
    Full Text Link to Item
  - Rubatt, J. M., A Alvarez Secord, E. Iversen, L. Grace, W. Soper, and A. Berchuck. “Regulation of angiogenic gene expression in p53 wild type and mutant ovarian cancer cells by hypoxia and radiation.” Gynecologic Oncology 108, no. 3 (March 1, 2008): S84–S84.
    Link to Item
  - Secord, Angeles Alvarez, John A. Blessing, Deborah K. Armstrong, William H. Rodgers, Zoe Miner, Mack N. Barnes, George Lewandowski, Robert S. Mannel, and Robert S. Gynecologic Oncology Group. “Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study.” Gynecol Oncol 108, no. 3 (March 2008): 493–99. https://doi.org/10.1016/j.ygyno.2007.11.029.
    Full Text Link to Item
  - Kirkpatrick, John P., Zahid N. Rabbani, Rex C. Bentley, Matt E. Hardee, Seth Karol, Jeffrey Meyer, Egbert Oosterwijk, et al. “Elevated CAIX Expression is Associated with an Increased Risk of Distant Failure in Early-Stage Cervical Cancer.” Biomark Insights 3 (February 1, 2008): 45–55. https://doi.org/10.4137/bmi.s570.
    Full Text Link to Item
  - Greer, Benjamin E., Wui-Jin Koh, Nadeem Abu-Rustum, Michael A. Bookman, Robert E. Bristow, Susana Campos, Kathleen R. Cho, et al. “Cervical cancer.” J Natl Compr Canc Netw 6, no. 1 (January 2008): 14–36. https://doi.org/10.6004/jnccn.2008.0003.
    Full Text Link to Item
  - Jewell, Elizabeth L., Shalini Kulasingam, Evan R. Myers, Angeles Alvarez Secord, and Laura J. Havrilesky. “Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis.” Gynecol Oncol 107, no. 3 (December 2007): 532–40. https://doi.org/10.1016/j.ygyno.2007.08.056.
    Full Text Link to Item
  - Alvarez Secord, Angeles, Laura J. Havrilesky, Victoria Bae-Jump, Jeanette Chin, Brian Calingaert, Amy Bland, Teresa L. Rutledge, Andrew Berchuck, Daniel L. Clarke-Pearson, and Paola A. Gehrig. “The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.” Gynecol Oncol 107, no. 2 (November 2007): 285–91. https://doi.org/10.1016/j.ygyno.2007.06.014.
    Full Text Link to Item
  - Havrilesky, Laura J., Angeles Alvarez Secord, Shalini Kulasingam, and Evan Myers. “Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.” Gynecol Oncol 107, no. 2 (November 2007): 211–18. https://doi.org/10.1016/j.ygyno.2007.06.029.
    Full Text Link to Item
  - Rankins, N Calloway, A Alvarez Secord, E. Jewell, L. J. Havrilesky, J. T. Soper, and E. Myers. “Cost-effectiveness of adjuvant radiotherapy in intermediate risk endometrial cancer.” Gynecol Oncol 106, no. 2 (August 2007): 388–93. https://doi.org/10.1016/j.ygyno.2007.04.015.
    Full Text Link to Item
  - Huh, W. K., J. M. Straughn, A. Mariani, K. C. Podratz, L. J. Havrilesky, A. Alvarez-Secord, M. A. Gold, et al. “Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience.” Int J Gynecol Cancer 17, no. 4 (July 2007): 886–89. https://doi.org/10.1111/j.1525-1438.2007.00858.x.
    Full Text Link to Item
  - Mutch, David G., Mauro Orlando, Tiana Goss, Michael G. Teneriello, Alan N. Gordon, Scott D. McMeekin, Yanping Wang, et al. “Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.” J Clin Oncol 25, no. 19 (July 1, 2007): 2811–18. https://doi.org/10.1200/JCO.2006.09.6735.
    Full Text Link to Item
  - Secord, Angeles Alvarez, Kathleen M. Darcy, Alan Hutson, Paula S. Lee, Laura J. Havrilesky, Lisa A. Grace, Andrew Berchuck, and Andrew Gynecologic Oncology Group study. “Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study.” Gynecol Oncol 106, no. 1 (July 2007): 221–32. https://doi.org/10.1016/j.ygyno.2007.03.021.
    Full Text Link to Item
  - Havrilesky, Laura J., Angeles Alvarez Secord, Victoria Bae-Jump, Tina Ayeni, Brian Calingaert, Daniel L. Clarke-Pearson, Andrew Berchuck, and Paola A. Gehrig. “Outcomes in surgical stage I uterine papillary serous carcinoma.” Gynecol Oncol 105, no. 3 (June 2007): 677–82. https://doi.org/10.1016/j.ygyno.2007.01.041.
    Full Text Link to Item
  - Alvarez Secord, Angeles, Paola A. Gehrig, Laura J. Havrilesky, Victoria Bae-Jump, Jeannette Chin, Brian Calingaert, Amy Bland, Teresa Rutledge, Andrew Berchuck, and Daniel L. Clarke-Pearson. “The role of multimodality adjuvant chemotherapy and radiation in women with advanced-stage endometrial cancer.” Gynecologic Oncology 104, no. 3 (March 1, 2007): S6–S6.
    Link to Item
  - Havrilesky, Laura J., Janiel M. Cragun, Brian Calingaert, Angeles Alvarez Secord, Fidel A. Valea, Daniel L. Clarke-Pearson, Andrew Berchuck, and John T. Soper. “The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer.” Gynecol Oncol 104, no. 2 (February 2007): 401–5. https://doi.org/10.1016/j.ygyno.2006.08.027.
    Full Text Link to Item
  - Secord, Angeles Alvarez, Laura J. Havrilesky, Michael E. Carney, John T. Soper, Daniel L. Clarke-Pearson, Gustavo C. Rodriguez, and Andrew Berchuck. “Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer.” Int J Clin Oncol 12, no. 1 (February 2007): 31–36. https://doi.org/10.1007/s10147-006-0619-9.
    Full Text Link to Item
  - Soper, J. T., A. A. Secord, L. J. Havrilesky, A. Berchuck, and D. L. Clarke-Pearson. “Comparison of gracilis and rectus abdominis myocutaneous flap neovaginal reconstruction performed during radical pelvic surgery: flap-specific morbidity.” Int J Gynecol Cancer 17, no. 1 (January 2007): 298–303. https://doi.org/10.1111/j.1525-1438.2007.00784.x.
    Full Text Link to Item
  - Secord, A. A., and A. Berchuck. “Targeted bio weapons in the war against gynecologic cancers.” Contemporary Ob/Gyn 51, no. 10 (October 1, 2006): 48–54.
  - Lutman, Christopher V., Laura J. Havrilesky, Janiel M. Cragun, Angeles Alvarez Secord, Brian Calingaert, Andrew Berchuck, Daniel L. Clarke-Pearson, and John T. Soper. “Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology.” Gynecologic Oncology 102, no. 1 (July 2006): 92–97. https://doi.org/10.1016/j.ygyno.2005.11.032.
    Full Text
  - Gynecologic Oncology Group, Andrew, Angeles Alvarez Secord, Paula S. Lee, Kathleen M. Darcy, Laura J. Havrilesky, Lisa A. Grace, Jeffrey R. Marks, and Andrew Berchuck. “Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study.” Gynecol Oncol 101, no. 3 (June 2006): 390–97. https://doi.org/10.1016/j.ygyno.2006.02.014.
    Full Text Link to Item
  - Jewell, E., A. A. Secord, T. Brotherton, and A. Berchuck. “Use of trastuzumab in the treatment of metastatic endometrial cancer.” Int J Gynecol Cancer 16, no. 3 (May 2006): 1370–73. https://doi.org/10.1111/j.1525-1438.2006.00543.x.
    Full Text Link to Item
  - Jones, Ellen, Angeles Alvarez Secord, Leonard R. Prosnitz, Thaddeus V. Samulski, James R. Oleson, Andrew Berchuck, Daniel Clarke-Pearson, John Soper, Mark W. Dewhirst, and Zeljko Vujaskovic. “Intra-peritoneal cisplatin and whole abdomen hyperthermia for relapsed ovarian carcinoma.” Int J Hyperthermia 22, no. 2 (March 2006): 161–72. https://doi.org/10.1080/02656730500515270.
    Full Text Link to Item
  - Havrilesky, Laura J., Janiel M. Cragun, Brian Calingaert, Ingrid Synan, Angeles Alvarez Secord, John T. Soper, Daniel L. Clarke-Pearson, and Andrew Berchuck. “Resection of lymph node metastases influences survival in stage IIIC endometrial cancer.” Gynecol Oncol 99, no. 3 (December 2005): 689–95. https://doi.org/10.1016/j.ygyno.2005.07.014.
    Full Text Link to Item
  - Alvarez Secord, A., E. L. Jones, C. A. Hahn, W. P. Petros, D. Yu, L. J. Havrilesky, J. T. Soper, et al. “Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer.” Int J Hyperthermia 21, no. 4 (June 2005): 333–47. https://doi.org/10.1080/02656730500110155.
    Full Text Link to Item
  - Hahn, C. A., E. L. Jones, J. L. Blivin, L. L. Sanders, D. Yu, M. W. Dewhirst, A. A. Secord, and L. R. Prosnitz. “Prospective assessment of quality of life in ovarian cancer patients receiving whole abdomen hyperthermia and liposomal doxorubicin.” Int J Hyperthermia 21, no. 4 (June 2005): 349–57. https://doi.org/10.1080/02656730400022260.
    Full Text Link to Item
  - Cragun, Janiel M., Laura J. Havrilesky, Brian Calingaert, Ingrid Synan, Angeles Alvarez Secord, John T. Soper, Daniel L. Clarke-Pearson, and Andrew Berchuck. “Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer.” J Clin Oncol 23, no. 16 (June 1, 2005): 3668–75. https://doi.org/10.1200/JCO.2005.04.144.
    Full Text Link to Item
  - Soper, J. T., L. J. Havrilesky, A. A. Secord, A. Berchuck, and D. L. Clarke-Pearson. “Rectus abdominis myocutaneous flaps for neovaginal reconstruction after radical pelvic surgery.” Int J Gynecol Cancer 15, no. 3 (May 2005): 542–48. https://doi.org/10.1111/j.1525-1438.2005.15322.x.
    Full Text Link to Item
  - Soper, John T., Angeles Alvarez Secord, Laura J. Havrilesky, Andrew Berchuck, and Daniel L. Clarke-Pearson. “Rectus abdominis myocutaneous and myoperitoneal flaps for neovaginal reconstruction after radical pelvic surgery: comparison of flap-related morbidity.” Gynecol Oncol 97, no. 2 (May 2005): 596–601. https://doi.org/10.1016/j.ygyno.2005.01.032.
    Full Text Link to Item
  - Ferrero, Simone, and Nicola Ragni. “Vascular endothelial growth factor, persistent disease, and survival in ovarian cancer.” Gynecol Oncol 96, no. 1 (January 2005): 265. https://doi.org/10.1016/j.ygyno.2004.09.032.
    Full Text Link to Item
  - Secord, A. A. “Vascular endothelial growth factor, persistent disease, and survival in ovarian cancer - Reply.” Gynecologic Oncology 96, no. 1 (January 1, 2005): 265–66. https://doi.org/10.1016/j.ygyno.2004.10.008.
    Full Text Link to Item
  - Berchuck, A., A. A. Secord, L. J. Havrilesky, R. Wenham, J. T. Soper, and D. L. Clarke-Pearson. “Phase I/II trial of combination topotecan and vinorelbine in patients with refractory gynecologic cancer.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 5152.
    Link to Item
  - Secord, A. A., E. Jones, C. A. Hahn, L. J. Havrilesky, J. T. Soper, A. Berchuck, D. L. Clarke-Pearson, L. R. Prosnitz, and M. W. Dewhirst. “Phase I/II trial of intravenous liposomal doxorubicin and whole abdomen hyperthermia in patients with refractory ovarian cancer.” J Clin Oncol 22, no. 14_suppl (July 15, 2004): 5089.
    Link to Item
  - Alvarez Secord, Angeles, Robyn Sayer, Stacey A. Snyder, Gloria Broadwater, Gustavo C. Rodriguez, Andrew Berchuck, and Kimberly Blackwell. “The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer.” Gynecol Oncol 94, no. 1 (July 2004): 74–79. https://doi.org/10.1016/j.ygyno.2004.03.043.
    Full Text Link to Item
  - Moller, Karen A., Paola A. Gehrig, Linda Van Le, Angeles Alvarez Secord, and John Schorge. “The role of optimal debulking in advanced stage serous carcinoma of the uterus.” Gynecol Oncol 94, no. 1 (July 2004): 170–74. https://doi.org/10.1016/j.ygyno.2004.03.040.
    Full Text Link to Item
  - Havrilesky, Laura J., Charles A. Leath, Warner Huh, Brian Calingaert, Rex C. Bentley, John T. Soper, and Angeles Alvarez Secord. “Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer.” Gynecol Oncol 93, no. 2 (May 2004): 429–34. https://doi.org/10.1016/j.ygyno.2004.01.038.
    Full Text Link to Item
  - Berchuck, A., A. A. Alvarez, and J. E. Stout. “Abdominal pain and bloating in two 20-something patients.” Contemporary Ob/Gyn 48, no. 1 (December 1, 2003): 51–58.
  - Roth, Ted M., Angeles Alvarez Secord, Laura J. Havrilesky, Ellen Jones, and Daniel L. Clarke-Pearson. “High dose rate intraoperative radiotherapy for recurrent cervical cancer and nodal disease.” Gynecol Oncol 91, no. 1 (October 2003): 258–60. https://doi.org/10.1016/s0090-8258(03)00443-8.
    Full Text Link to Item
  - Alvarez, A. A., and D. L. Clarke-Pearson. “Platinum-resistant and refractory ovarian cancer: Second-line treatment options.” American Journal of Cancer 2, no. 1 (September 8, 2003): 1–13. https://doi.org/10.2165/00024669-200302010-00001.
    Full Text
  - Jones, Ellen L., Thaddeus V. Samulski, Mark W. Dewhirst, Angeles Alvarez-Secord, Andrew Berchuck, Daniel Clarke-Pearson, Laura J. Havrilesky, John Soper, and Leonard R. Prosnitz. “A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma.” Cancer 98, no. 2 (July 15, 2003): 277–82. https://doi.org/10.1002/cncr.11475.
    Full Text Link to Item
  - Havrilesky, Laura J., Terence Z. Wong, Angeles Alvarez Secord, Andrew Berchuck, Daniel L. Clarke-Pearson, and Ellen L. Jones. “The role of PET scanning in the detection of recurrent cervical cancer.” Gynecol Oncol 90, no. 1 (July 2003): 186–90. https://doi.org/10.1016/s0090-8258(03)00256-7.
    Full Text Link to Item
  - Havrilesky, Laura J., Angeles A. Alvarez, Robyn A. Sayer, Johnathan M. Lancaster, John T. Soper, Andrew Berchuck, Daniel L. Clarke-Pearson, Gustavo C. Rodriguez, and Michael E. Carney. “Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.” Gynecol Oncol 88, no. 1 (January 2003): 51–57. https://doi.org/10.1006/gyno.2002.6859.
    Full Text Link to Item
  - Havrilesky, L. J., A. A. Alvarez, R. S. Whitaker, J. R. Marks, and A. Berchuck. “Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.” Gynecol Oncol 83, no. 3 (December 2001): 491–500. https://doi.org/10.1006/gyno.2001.6464.
    Full Text Link to Item
  - Stout, J. E., C. W. Woods, A. A. Alvarez, A. Berchuck, and C. Dukes Hamilton. “Mycobacterium bovis peritonitis mimicking ovarian cancer in a young woman.” Clin Infect Dis 33, no. 4 (August 15, 2001): E14–16. https://doi.org/10.1086/321908.
    Full Text Link to Item
  - Alvarez, A. A., J. R. Axelrod, R. S. Whitaker, P. D. Isner, R. C. Bentley, R. K. Dodge, and G. C. Rodriguez. “Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.” Gynecol Oncol 82, no. 2 (August 2001): 273–78. https://doi.org/10.1006/gyno.2001.6287.
    Full Text Link to Item
  - Alvarez, A. A., A. R. Lambers, J. M. Lancaster, G. L. Maxwell, S. Ali, C. Gumbs, A. Berchuck, and P. A. Futreal. “Allele loss on chromosome 1p36 in epithelial ovarian cancers.” Gynecol Oncol 82, no. 1 (July 2001): 94–98. https://doi.org/10.1006/gyno.2001.6175.
    Full Text Link to Item
  - Alvarez, A. A., G. L. Maxwell, and G. C. Rodriguez. “Vacuum-assisted closure for cutaneous gastrointestinal fistula management.” Gynecol Oncol 80, no. 3 (March 2001): 413–16. https://doi.org/10.1006/gyno.2000.6092.
    Full Text Link to Item
  - Maxwell, G. L., J. I. Risinger, A. A. Alvarez, J. C. Barrett, and A. Berchuck. “Favorable survival associated with microsatellite instability in endometrioid endometrial cancers.” Obstet Gynecol 97, no. 3 (March 2001): 417–22. https://doi.org/10.1016/s0029-7844(00)01165-0.
    Full Text Link to Item
  - Alvarez, A. A., W. F. Moore, S. J. Robboy, R. C. Bentley, C. Gumbs, P. A. Futreal, and A. Berchuck. “K-ras mutations in Müllerian inclusion cysts associated with serous borderline tumors of the ovary.” Gynecol Oncol 80, no. 2 (February 2001): 201–6. https://doi.org/10.1006/gyno.2000.6066.
    Full Text Link to Item
  - Maxwell, G. L., J. I. Risinger, K. A. Hayes, A. A. Alvarez, R. K. Dodge, J. C. Barrett, and A. Berchuck. “Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers.” Clin Cancer Res 6, no. 8 (August 2000): 2999–3005.
    Link to Item
  - Kearney, P., A. Secord, and H. Zhang. “InVEST: interactive and visual edge selection tool for constructing evolutionary trees.” Pac Symp Biocomput, 2000, 242–53. https://doi.org/10.1142/9789814447331_0023.
    Full Text Link to Item
  - Berchuck, A., A. Alvarez, and P. A. Futreal. “Prognosis of BRCA1 and 2-associated ovarian cancers.” Cme Journal of Gynecologic Oncology 4, no. 1 (December 1, 1999): 108–11.
  - Alvarez, A. A., H. R. Krigman, R. S. Whitaker, R. K. Dodge, and G. C. Rodriguez. “The prognostic significance of angiogenesis in epithelial ovarian carcinoma.” Clin Cancer Res 5, no. 3 (March 1999): 587–91.
    Link to Item
  - Maxwell, G. L., J. I. Risinger, H. Shaw, A. Alvarez, J. C. Barrett, P. A. Futreal, and A. Berchuck. “Mutations in the PTEN tumor suppressor gene in cervical carcinomas.” International Journal of Gynecological Cancer 8, no. 6 (December 1, 1998): 489–93. https://doi.org/10.1046/j.1525-1438.1998.98102.x.
    Full Text
  - Secord, A. A., R. Sayer, S. A. Snyder, G. Broadwater, G. C. Rodriguez, A. Berchuck, and K. Blackwell. “Second-look laparotomy in ovarian cancer.” Gynecologic Oncology 55, no. 3 (January 1, 1994): S122–27. https://doi.org/10.1006/gyno.1994.1350.
    Full Text
- Book Sections
  - Secord, A. A., and S. Siamakpour-Reihani. “Angiogenesis.” In Translational Advances in Gynecologic Cancers, 79–109, 2017. https://doi.org/10.1016/B978-0-12-803741-6.00005-7.
    Full Text
  - Romano-Fitzgerald, S., A. B. De Meritens, A. A. Secord, and E. C. Kohn. “Invasion, metastasis, and angiogenesis.” In Principles and Practice of Gynecologic Oncology: Sixth Edition, 72–88, 2013.
- Conference Papers
  - Brown, Jubilee, Alice Barr, Yingao Zhang, Brittany Davidson, Angeles Alvarez Secord, Lane Drury, Erin Crane, David Tait, R Wendel Naumann, and Leah McNally. “A multi-institutional study of minimally invasive surgery compared to laparotomy for interval debulking after neoadjuvant chemotherapy in women with advanced ovarian cancer.” In Gynecologic Oncology, 162:S20–S20, 2021.
    Link to Item
  - Davidson, Brittany, Jessie Ehrisman, Karen Monuszko, Sarah Paraghamian, Victoria Bae-Jump, Yuan Wu, Andrew Berchuck, et al. “HOPE & Healing: a randomized pilot study of structured palliative care referrals in recurrent ovarian cancer.” In Gynecologic Oncology, 162:S169–S169, 2021.
    Link to Item
  - Gaillard, Stephanie, Linda Duska, Gloria Broadwater, Leah McNally, Paula Lee, Brittany Davidson, Rebecca Previs, et al. “AdoRN Trial: Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly-diagnosed advanced-stage epithelial ovarian cancer.” In Gynecologic Oncology, 162:S61–S61, 2021.
    Link to Item
  - Nixon, Andrew, Joyce Liu, Niya Xiong, Herbert I. Hurwitz, Jing Lyu, Yingmiao Liu, Mark Starr, et al. “Blood-based biomarkers in patients with platinum-sensitive and resistant ovarian cancer treated with olaparib and cediranib: results from the UM9825 trial.” In Gynecologic Oncology, 162:S99–S99, 2021.
    Link to Item
  - O’Donnell, Jillian, Lindsey Buckingham, Tianran Hao, Angeles Alvarez Secord, Chunxiao Zhou, and Victoria Bae-Jump. “Ipatasertib, an oral AKT inhibitor, exhibits anti-proliferative and anti-tumorigenic effects in pre-clinical studies for endometrioid endometrial cancer: Endometrial Cancer Molecularly Targeted Therapy Consortium.” In Gynecologic Oncology, 162:S41–42, 2021.
    Link to Item
  - Watson, Catherine, Jessie Paradis, Andrew Berchuck, Keelia Clemens, Margaret Powell, Jinny Riedel, Noah Kauff, and Angeles Alvarez Secord. “Dual germline and somatic testing in women with high-grade epithelial ovarian, tubal, and peritoneal cancer: a prospective systemic quality improvement initiative.” In Gynecologic Oncology, 162:S144–S144, 2021.
    Link to Item
  - Arend, Rebecca Christian, Bradley J. Monk, Thomas J. Herzog, Jonathan A. Ledermann, Kathleen N. Moore, Angeles Alvarez Secord, Ronnie Shapira-Frommer, et al. “Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).” In Journal of Clinical Oncology, 39:TPS5599–TPS5599. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.tps5599.
    Full Text
  - Fuh, Katherine Cynthia, Thomas J. Herzog, Kathleen N. Moore, Tashanna K. N. Myers, B. J. Rimel, Joyce F. Liu, Angeles Alvarez Secord, et al. “A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66/AVB500-OC-004).” In Journal of Clinical Oncology, 39:TPS5605–TPS5605. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.tps5605.
    Full Text
  - Hamilton, Erika P., Camille Catherine Jackson, Ramez Nassef Eskander, Floor Jenniskens Backes, Vicky Makker, Fernanda Musa, Alexander Olawaiye, et al. “LIO-1: Lucitanib + nivolumab in patients with advanced solid tumors—Updated phase 1b results and initial experience in phase 2 ovarian cancer cohort.” In Journal of Clinical Oncology, 39:5538–5538. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.5538.
    Full Text
  - Secord, Angeles Alvarez, Sunil Gupta, Cathy Reddick, Jyoti Chauhan, Sarah Gill, John O. Schorge, Michael Gold, et al. “FLORA-5: Front-line chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab [PCO] versus chemotherapy (Paclitaxel-Carboplatin-Placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III double-blind placebo controlled multinational study.” In Journal of Clinical Oncology, 39:TPS5606–TPS5606. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.tps5606.
    Full Text
  - Buckingham, Lindsey, Jillian O’Donnell, Tianran Hao, Angeles Alvarez Secord, Chunxiao Zhou, and Victoria Bae-Jump. “Ipatasertib, an oral AKT inhibitor, effectively inhibits cell proliferation and migration, and induces apoptosis in endometrioid and serous endometrial cancer cell lines in vitro (Endometrial Cancer Molecularly Targeted Therapy Consortium).” In European Journal of Gynaecological Oncology, 42:387–88, 2021.
    Link to Item
  - Alvarez Secord, A., M. Bookman, R. Coleman, M. Dinh, N. Khandelwal, K. Benjamin, R. Kamalakar, D. Sullivan, and D. Cella. “16 Quality-adjusted (QA) progression-free survival analyses of veliparib + carboplatin/paclitaxel (CP) vs CP alone in patients with newly diagnosed ovarian cancer.” In Oral Plenary. BMJ Publishing Group Ltd, 2020. https://doi.org/10.1136/ijgc-2020-igcs.16.
    Full Text
  - Batinic-Haberle, Ines, Weina Duan, Li Du, Zhiqing Huang, Artak Tovmasyan, Zhipeng Cao, Shara Reihani, Ivan Spasojevic, Huaxin Sheng, and Angeles Alvarez Secord. “MnTnBuOE-2-PyP5+ Ascorbate in the Treatment of Ovarian Cancer.” In Free Radical Biology and Medicine, 159:S51–S51. Elsevier BV, 2020. https://doi.org/10.1016/j.freeradbiomed.2020.10.138.
    Full Text
  - Brown, J., A. Miller, K. Moxley, F. Backes, C. Nagel, D. Bender, D. Miller, et al. “RESULTS OF A RANDOMIZED PHASE II TRIAL OF PACLITAXEL AND CARBOPLATIN VERSUS BLEOMYCIN, ETOPOSIDE AND CISPLATIN FOR NEWLY DIAGNOSED AND RECURRENT CHEMONAIVE STROMAL OVARIAN TUMORS.” In International Journal of Gynecological Cancer, 30:A56–A56, 2020.
    Link to Item
  - Duska, L. R., G. Petroni, J. Brown, D. Jelovac, K. N. Moore, W. P. McGuire, C. J. Darus, L. M. Barroilhet, and A. A. Secord. “A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.” In Gynecologic Oncology, 159:15–15. Elsevier BV, 2020. https://doi.org/10.1016/j.ygyno.2020.06.028.
    Full Text
  - Fader, A. N., D. M. Roque, E. R. Siegel, N. Buza, P. Hui, L. J. Havrilesky, A. A. Secord, et al. “Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress HER2/Neu (NCT01367002): Updated survival analysis.” In Gynecologic Oncology, 159:7–8. Elsevier BV, 2020. https://doi.org/10.1016/j.ygyno.2020.06.014.
    Full Text
  - Gaillard, S., G. Broadwater, W. S. Andrews, M. D. Starr, R. A. Previs, L. J. Havrilesky, B. A. Davidson, et al. “Pembrolizumab window study: Illuminating the immunologic landscape in gynecologic cancers.” In Gynecologic Oncology, 159:41–41. Elsevier BV, 2020. https://doi.org/10.1016/j.ygyno.2020.06.087.
    Full Text
  - Gonzalez, R., L. J. Havrilesky, A. A. Secord, E. R. Myers, J. A. Dottino, and H. A. Moss. “Just OK is not OK: How well does PARP inhibitor frontline maintenance therapy need to work in biomarker negative ovarian cancer for universal treatment to represent a value-based therapeutic option?” In Gynecologic Oncology, 159:21–22. Elsevier BV, 2020. https://doi.org/10.1016/j.ygyno.2020.06.043.
    Full Text
  - Puechl, A. M., S. Lim, L. A. Gatta, A. Lorenzo, A. N. Galanos, T. Truong, A. Berchuck, et al. “A systematic outpatient quality improvement intervention results in earlier goals of care conversations between high-risk gynecologic cancer patients and their providers.” In Gynecologic Oncology, 159:306–306. Elsevier BV, 2020. https://doi.org/10.1016/j.ygyno.2020.05.549.
    Full Text
  - Watson, C. H., L. Fish, L. J. Havrilesky, A. A. Secord, and B. A. Davidson. “The gynecologic oncology patient experience with oral anti-cancer therapy: A quantitative and qualitative analysis of medication adherence.” In Gynecologic Oncology, 159:285–285. Elsevier BV, 2020. https://doi.org/10.1016/j.ygyno.2020.05.499.
    Full Text
  - Colombo, N., Y. Antill, M. P. Barretina Ginesta, K. Harano, E. Hudson, F. Marmé, C. Marth, et al. “884TiP AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer.” In Annals of Oncology, 31:S647–S647. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.08.2090.
    Full Text
  - Randall, L. M., D. M. O’Malley, B. J. Monk, R. L. Coleman, R. E. O’Cearbhaill, S. Gaillard, S. Adams, et al. “883TiP MOONSTONE/GOG-3032: A phase II, open-label, single-arm study to evaluate the efficacy and safety of niraparib + dostarlimab in patients with platinum-resistant ovarian cancer.” In Annals of Oncology, 31:S646–47. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.08.1022.
    Full Text
  - Arend, Rebecca Christian, Bradley J. Monk, Robert Allen Burger, Thomas J. Herzog, Jonathan A. Ledermann, Kathleen N. Moore, Angeles Alvarez Secord, et al. “Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).” In Journal of Clinical Oncology, Vol. 38, 2020.
    Link to Item
  - Liu, Joyce F., Mark F. Brady, Ursula A. Matulonis, Austin Miller, Elise C. Kohn, Elizabeth M. Swisher, William P. Tew, et al. “A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.” In Journal of Clinical Oncology, Vol. 38, 2020.
    Link to Item
  - Moss, Haley, Angeles Alvarez Secord, Jessica Perhanidis, and Carol Hawkes. “Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: Are some patients missing out?” In Journal of Clinical Oncology, Vol. 38, 2020.
    Link to Item
  - Havrilesky, L. J., S. L. Lim, J. A. Ehrisman, A. Lorenzo, Alvarez A. Secord, J. C. Yang, F. R. Johnson, and S. D. Reed. “WOMEN'S PREFERENCES ON BENEFITS, RISKS, AND SIDE EFFECTS OF MAINTENANCE PARP INHIBITOR THERAPY IN OVARIAN CANCER.” In Value in Health, 22:S541–S541. ELSEVIER SCIENCE INC, 2019.
    Link to Item
  - Gershenson, D. M., A. Miller, W. Brady, J. Paul, K. Carty, W. Rodgers, D. Millan, et al. “A randomized phase II/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer.” In Annals of Oncology, Vol. 30. OXFORD UNIV PRESS, 2019.
    Link to Item
  - Gay, L., J. C. Schink, J. D. Wright, S. B. Lele, P. C. Mayor, K. Odunsi, A. Hemmerich, et al. “Targeting family genomic alterations in gynecological malignancies.” In Gynecologic Oncology, 154:89–89. Elsevier BV, 2019. https://doi.org/10.1016/j.ygyno.2019.04.210.
    Full Text
  - Matulonis, U. A., B. J. Monk, A. A. Secord, M. A. Geller, D. S. Miller, N. G. Cloven, G. F. Fleming, et al. “Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer.” In Gynecologic Oncology, 154:3–3. Elsevier BV, 2019. https://doi.org/10.1016/j.ygyno.2019.04.017.
    Full Text
  - Moss, H. A., L. J. Havrilesky, N. D. Kauff, and A. A. Secord. “Maintenance therapy utilization in platinum-sensitive recurrent epithelial ovarian cancer: A 'real-world' analysis.” In Gynecologic Oncology, 154:204–204. Elsevier BV, 2019. https://doi.org/10.1016/j.ygyno.2019.04.474.
    Full Text
  - Puechl, A. M., K. C. Strickland, E. J. Tanner, T. Murdock, G. Broadwater, J. A. Ehrisman, P. S. Lee, A. A. Secord, and L. Havrilesky. “Association between isolated tumor cells and recurrence in stage I endometrial cancer.” In Gynecologic Oncology, 154:172–172. Elsevier BV, 2019. https://doi.org/10.1016/j.ygyno.2019.04.401.
    Full Text
  - Salinaro, J. R., R. B. Boccaccio, J. A. Ehrisman, L. J. Havrilesky, A. A. Secord, K. N. Moore, and B. A. Davidson. “Rate of venous thromboembolism during neoadjuvant chemotherapy for advanced ovarian cancer.” In Gynecologic Oncology, 154:29–30. Elsevier BV, 2019. https://doi.org/10.1016/j.ygyno.2019.04.071.
    Full Text
  - Secord, A. A., R. A. Previs, B. Pothuri, K. C. Strickland, L. Gay, D. A. Levine, B. A. Davidson, and J. A. Elvin. “Molecular driven endometrial cancer therapy (MODEL): A prospective paradigm using molecular tumor profiling to direct therapy in women with advanced/recurrent endometrial cancer.” In Gynecologic Oncology, 154:248–248. Elsevier BV, 2019. https://doi.org/10.1016/j.ygyno.2019.04.572.
    Full Text
  - Yen, T. T., A. L. Beavis, R. L. Stone, S. Wethington, C. E. Carr, J. Son, LJ Moulton Chambers, et al. “Early-stage endometrial cancer with lymphovascular space invasion: Chemotherapy improves progression free survival and reduces distant metastases.” In Gynecologic Oncology, 154:287–88. Elsevier BV, 2019. https://doi.org/10.1016/j.ygyno.2019.04.675.
    Full Text
  - Gatta, L. A., I. V. Rodriguez, K. C. Strickland, J. B. Gilner, C. Grotegut, J. Ronald, M. Bashir, A. James, P. S. Lee, and A. A. Secord. “Novel management of morbidly adherent placenta: Preliminary outcomes assessment of 13-year experience with prospective multidisciplinary algorithm.” In Gynecologic Oncology, 154:15–15. Elsevier BV, 2019. https://doi.org/10.1016/j.ygyno.2019.04.041.
    Full Text
  - Colombo, Nicoletta, Maria Pilar Barretina-Ginesta, Philip James Beale, Kenichi Harano, Emma Hudson, Frederik Marmé, Christian Marth, et al. “AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer.” In Journal of Clinical Oncology, 37:TPS5608–TPS5608. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.tps5608.
    Full Text
  - Havrilesky, Laura Jean, Stephanie Lim, Jui-Chen Yang, Amelia Lorenzo, Jessie A. Ehrisman, Angeles Alvarez Secord, Reed Johnson, and Shelby D. Reed. “Patient preferences for maintenance PARP therapy in ovarian cancer treatment.” In Journal of Clinical Oncology, 37:5558–5558. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.5558.
    Full Text
  - Powell, Matthew A., Virginia L. Filiaci, Martee Leigh Hensley, Helen Q. Huang, Kathleen N. Moore, Krishnansu Sujata Tewari, Larry J. Copeland, et al. “A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial.” In Journal of Clinical Oncology, 37:5500–5500. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.5500.
    Full Text
  - Previs, Rebecca Ann, Daniel Spinosa, Bryan M. Fellman, Amelia Lorenzo, Isabelle Mulder, May Mahmoud, Ahmed Enbaya, et al. “Bevacizumab beyond progression: Impact of subsequent bevacizumab retreatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.” In Journal of Clinical Oncology, 37:5557–5557. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.5557.
    Full Text
  - Watson, Catherine H., Brittany Anne Davidson, Laura Jean Havrilesky, Paula S. Lee, Leah McNally, Haley Moss, Rebecca A. Previs, et al. “Management of high, moderate, and low penetrance ovarian cancer susceptibility gene mutations: An assessment of current practice patterns.” In Journal of Clinical Oncology, 37:1536–1536. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.1536.
    Full Text
  - Moore, K. N., A. A. Secord, M. Geller, D. S. Miller, N. G. Cloven, G. F. Fleming, A. E. Wahner Hendrickson, et al. “QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset.” In Ann Oncol, 29 Suppl 8:viii337, 2018. https://doi.org/10.1093/annonc/mdy285.152.
    Full Text Link to Item
  - Coleman, R. L., D. Enserro, T. J. Herzog, P. Sabbatini, D. K. Armstrong, B. Kim, K. Fujiwara, et al. “GOG213.” In International Journal of Gynecological Cancer, 28:8–8. BMJ PUBLISHING GROUP, 2018.
    Link to Item
  - Coleman, R. L., D. Enserro, T. J. Herzog, P. Sabbatini, D. K. Armstrong, B. Kim, K. Fujiwara, et al. “A PHASE III RANDOMIZED CONTROLLED TRIAL OF SECONDARY CYTOREDUCTIVE SURGERY (SCS) FOLLOWED BY PLATINUM-BASED CHEMOTHERAPY (PC) PLATINUM-SENSITIVE, RECURRENT OVARIAN CANCER (PSOC) - SURGICAL PARAMETERS.” In International Journal of Gynecological Cancer, 28:52–52. BMJ PUBLISHING GROUP, 2018.
    Link to Item
  - Secord, A Alvarez, M. McCollum, B. Davidson, G. Broadwater, R. Squatrito, L. Havrilesky, A. Gabel, A. Nixon, and L. Duska. “PHASE II TRIAL OF NINTEDANIB IN PATIENTS WITH BEVACIZUMAB-RESISTANT RECURRENT EPITHELIAL OVARIAN, TUBAL, AND PERITONEAL CANCER.” In International Journal of Gynecological Cancer, 28:457–457. BMJ PUBLISHING GROUP, 2018.
    Link to Item
  - Cobb, L. P., A. Rickard, J. Herbert, G. Hanna, G. Palmer, S. Siamakpour-Reihani, Z. Huang, et al. “Targeting the TIE2 pathway with a novel small molecule vascular endothelial protein tyrosine phosphatase (VE-PTP) inhibitor in high-grade serous ovarian cancer.” In Gynecologic Oncology, 149:14–14. Elsevier BV, 2018. https://doi.org/10.1016/j.ygyno.2018.04.037.
    Full Text
  - Cobb, L. P., S. Siamakpour-Reihani, D. Zhang, K. Owzar, A. Berchuck, V. L. Bae-Jump, and A. A. Secord. “Obesity is associated with altered angiogenic gene expression in endometrioid endometrial cancer.” In Gynecologic Oncology, 149:177–78. Elsevier BV, 2018. https://doi.org/10.1016/j.ygyno.2018.04.404.
    Full Text
  - Dottino, J. A., H. A. Moss, K. H. Lu, A. A. Secord, and L. J. Havrilesky. “Are FDA-approved PARPi cost-effective as maintenance treatment of platinum-sensitive recurrent ovarian cancer?” In Gynecologic Oncology, 149:11–12. Elsevier BV, 2018. https://doi.org/10.1016/j.ygyno.2018.04.032.
    Full Text
  - Levine, D. A., D. S. Dizon, J. W. Carlson, V. L. Filiaci, M. A. Powell, A. A. Secord, K. S. Tewari, et al. “Predictive biomarkers of endometrial cancer response: Results from NRG Oncology/Gynecologic Oncology Group study 86P.” In Gynecologic Oncology, 149:12–13. Elsevier BV, 2018. https://doi.org/10.1016/j.ygyno.2018.04.034.
    Full Text
  - Mallen, A. R., V. L. Filiaci, D. A. Levine, K. Thiel, C. A. Aghajanian, X. Meng, E. Devor, et al. “Evidence for synthetic lethality between bevacizumab and chemotherapy in advanced, p53 null endometrial cancers.” In Gynecologic Oncology, 149:29–30. Elsevier BV, 2018. https://doi.org/10.1016/j.ygyno.2018.04.069.
    Full Text
  - Buechel, Megan, Danielle Enserro, Robert Allen Burger, Mark F. Brady, Katrina Wade, Angeles Alvarez Secord, Andrew B. Nixon, et al. “Correlation of imaging and plasma-based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC): A GOG 218 ancillary data analysis.” In Journal of Clinical Oncology, 36:5507–5507. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5507.
    Full Text
  - Coleman, Robert L., Danielle Enserro, Nick Spirtos, Thomas J. Herzog, Paul Sabbatini, Deborah Kay Armstrong, Byoung Kim, et al. “A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study.” In Journal of Clinical Oncology, 36:5501–5501. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5501.
    Full Text
  - Davidson, Brittany Anne, Jonathan Foote, Jessie Ehrisman, Jui-Chen Yang, Shelby D. Reed, Reed Johnson, Paula S. Lee, Angeles Alvarez Secord, Andrew Berchuck, and Laura Jean Havrilesky. “What factors drive the choice of a genetic test? A prospective study of the preferences of women with ovarian cancer.” In Journal of Clinical Oncology, 36:e13621–e13621. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e13621.
    Full Text
  - Friedlander, Michael, John K. Chan, Jim Java, Deborah K. Armstrong, Maurie Markman, Thomas J. Herzog, Bradley J. Monk, et al. “Characterization and predictors of long term (≥ 10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer patients.” In Journal of Clinical Oncology, 36:5556–5556. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5556.
    Full Text
  - Gaillard, Stephanie, Laurie M. Gay, Meghan Steiner, Kaitlyn Andreano, Brittany Anne Davidson, Laura Jean Havrilesky, Angeles Alvarez Secord, et al. “Assessment of activating estrogen receptor 1 (ESR1) mutations in gynecologic malignancies.” In Journal of Clinical Oncology, 36:5590–5590. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5590.
    Full Text
  - Moore, Kathleen N., Angeles Alvarez Secord, Melissa Ann Geller, David S. Miller, Noelle Gillette Cloven, Gini F. Fleming, Andrea Elisabeth Wahner Hendrickson, et al. “QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.” In Journal of Clinical Oncology, 36:5514–5514. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5514.
    Full Text
  - Salinaro, Julia, Jessie Ehrisman, Angeles Alvarez Secord, and Brittany Anne Davidson. “Incidence of venous thromboembolism among patients receiving neoadjuvant chemotherapy for advanced ovarian cancer.” In Journal of Clinical Oncology, 36:e17531–e17531. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e17531.
    Full Text
  - Santin, A. D., A. Fader, D. M. Roque, S. Eric, N. Buza, H. Pei, O. Abdelghany, et al. “Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002).” In International Journal of Gynecological Cancer, 27:15–16. LIPPINCOTT WILLIAMS & WILKINS, 2017.
    Link to Item
  - Cobb, L. P., A. A. Secord, C. Jiang, D. Zhang, S. Gaillard, A. Berchuck, K. Owzar, A. Nixon, and S. Siamakpour-Reihani. “Differential expression of immune-related genes in high-grade ovarian serous carcinoma (HGSC): A platform for drug and biomarker discovery.” In Gynecologic Oncology, 145:36–37. Elsevier BV, 2017. https://doi.org/10.1016/j.ygyno.2017.03.095.
    Full Text
  - Foote, J. R., M. I. Liang, A. A. Secord, E. Jewell, D. E. Cohn, B. J. Rimel, and L. J. Havrilesky. “Prospective patient-elicited value assessments of options in the primary treatment of ovarian cancer.” In Gynecologic Oncology, 145:45–46. Elsevier BV, 2017. https://doi.org/10.1016/j.ygyno.2017.03.115.
    Full Text
  - Lee, P. S., D. Bloom, J. A. Ehrisman, L. J. Havrilesky, A. A. Secord, V. L. Bae-Jump, and J. A. Tulsky. “Patient, caregiver and physician perceptions of palliative care in ovarian cancer: Insights from the HOPE prospective pilot study.” In Gynecologic Oncology, 145:200–201. Elsevier BV, 2017. https://doi.org/10.1016/j.ygyno.2017.03.460.
    Full Text
  - Tanner, E. J., A. M. Puechl, K. Levinson, L. J. Havrilesky, A. K. Sinno, A. A. Secord, A. N. Fader, and P. S. Lee. “Use of a novel sentinel lymph node mapping algorithm reduces pelvic lymphadenectomy rates in patients with low-grade endometrial cancer.” In Gynecologic Oncology, 145:135–36. Elsevier BV, 2017. https://doi.org/10.1016/j.ygyno.2017.03.316.
    Full Text
  - Duska, Linda R., Jubilee Brown, Danijela Jelovac, Kathleen N. Moore, William P. McGuire, Christopher Darus, Lisa Marie Barroilhet, and Angeles Alvarez Secord. “A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemictabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.” In Journal of Clinical Oncology, 35:5532–5532. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.5532.
    Full Text
  - Foote, Jonathan, Laura Jean Havrilesky, Elizabeth Lin Jewell, Charlotte Gamble, Jessie Ehrisman, Gloria Broadwater, Robert L. Coleman, David E. Cohn, and Angeles Alvarez Secord. “Management of platinum-sensitive recurrent ovarian cancer (PSROC) in the era of biologics: Can ASCO’s net health benefits (NHB) inform our decisions?” In Journal of Clinical Oncology, 35:5544–5544. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.5544.
    Full Text
  - Gaillard, Stephanie, Chelsae Dumbauld, Alyssa Bilewski, Jessie A. Ehrisman, Angeles Alvarez Secord, Laura Jean Havrilesky, Andrew Berchuck, Kent Weinhold, Cliburn Chan, and John Yi. “Evaluating the repertoire of immune checkpoint markers expressed on peripheral and ascites CD8+ T cells in ovarian cancer.” In Journal of Clinical Oncology, 35:5571–5571. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.5571.
    Full Text
  - Davidson, Brittany Anne, Robert Squatrito, Linda R. Duska, Laura Jean Havrilesky, Nyssa Schwager, Michael McCollum, Sanja Arapovic, and Angeles Alvarez Secord. “Phase II evaluation of nintedanib in the treatment of bevacizumab-resistant persistent/recurrent ovarian, fallopian tube, or primary peritoneal carcinoma.” In Journal of Clinical Oncology, 34:TPS5601–TPS5601. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.tps5601.
    Full Text
  - Foote, Jonathan, Margaret Liang, Angeles Alvarez Secord, David E. Cohn, and Laura Jean Havrilesky. “Patient preference-weighted assessments using the ASCO value framework in recurrent, platinum-sensitive ovarian cancer.” In Journal of Clinical Oncology, 34:6630–6630. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.6630.
    Full Text
  - Matulonis, Ursula A., Amit M. Oza, Angeles Alvarez Secord, Lynda D. Roman, Sarah Patricia Blagden, Susana N. Banerjee, J. C. Elkas, et al. “Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study.” In Journal of Clinical Oncology, 34:5547–5547. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.5547.
    Full Text
  - Secord, Angeles Alvarez, David Tritchler, Yingmiao Liu, Mark D. Starr, John C. Brady, Heather A. Lankes, Herbert Hurwitz, et al. “Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.” In Journal of Clinical Oncology, 34:5521–5521. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.5521.
    Full Text
  - Ehrisman, Jessie A., Sara Abbott, Zach Harmon, Angeles Alvarez Secord, Andrew Berchuck, Paula S. Lee, Fidel A. Valea, et al. “Prospective Evaluation of Lymph Node Processing at Staging Surgery for High-Grade Endometrial Cancer.” In Modern Pathology, 29:282A-282A. NATURE PUBLISHING GROUP, 2016.
    Link to Item
  - Aghajanian, Carol, Virginia L. Filiaci, Don S. Dizon, Jay Carlson, Matthew A. Powell, Angeles Alvarez Secord, Krishnansu Sujata Tewari, et al. “A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P.” In Journal of Clinical Oncology, 33:5500–5500. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.5500.
    Full Text
  - Davidson, B. A., D. B. Mannschreck, G. Broadwater, M. Lopez-Acevedo, P. S. Lee, L. J. Havrilesky, F. A. Valea, A. Berchuck, and A. A. Secord. “Findings at laparoscopy, not debulking status, are associated with survival in advanced stage ovarian cancer after neoadjuvant chemotherapy.” In Gynecologic Oncology, 137:111–111. Elsevier BV, 2015. https://doi.org/10.1016/j.ygyno.2015.01.276.
    Full Text
  - Ehrisman, J. A., A. A. Secord, A. Berchuck, P. S. Lee, N. Di Santo, F. A. Valea, and L. J. Havrilesky. “Sentinel lymph node mapping in women with high risk histology endometrial cancer.” In Gynecologic Oncology, 137:93–93. Elsevier BV, 2015. https://doi.org/10.1016/j.ygyno.2015.01.229.
    Full Text
  - Fuh, K. C., A. A. Secord, K. S. Bevis, W. K. Huh, K. Blansit, E. Rosenfeld, L. Hu, et al. “Disease stabilization versus response after bevacizumab treatment in recurrent ovarian cancer: How do we determine clinical efficacy?” In Gynecologic Oncology, 137:56–56. Elsevier BV, 2015. https://doi.org/10.1016/j.ygyno.2015.01.130.
    Full Text
  - Lopez-Acevedo, M., A. H. Buchanan, A. A. Secord, P. S. Lee, C. Fountain, E. R. Myers, D. E. Cohn, S. D. Reed, and L. J. Havrilesky. “Cost comparison among different genetic testing strategies in women with epithelial ovarian cancer.” In Gynecologic Oncology, 137:171–171. Elsevier BV, 2015. https://doi.org/10.1016/j.ygyno.2015.01.429.
    Full Text
  - Nakayama, J., E. Saks, E. Pelkofski, J. Edwards, J. E. Stine, A. A. Secord, P. A. Gehrig, and L. Duska. “Laparoscopy compared to laparotomy in the management of granulosa cell tumors of the ovary.” In Gynecologic Oncology, 137:168–168. Elsevier BV, 2015. https://doi.org/10.1016/j.ygyno.2015.01.421.
    Full Text
  - Teoh, Deanna, William J. Lowery, Xiaoyin Jiang, Jessie Ehrisman, Paige Halvorson, Gloria Broadwater, Rex Bentley, et al. “Vaginal cuff thermal injury by mode of colpotomy at total laparoscopic hysterectomy: a randomized clinical trial.” In J Minim Invasive Gynecol, 22:227–33, 2015. https://doi.org/10.1016/j.jmig.2014.10.002.
    Full Text Link to Item
  - Fleming, Gini, Sharad Ghamande, Yvonne Lin, Angeles Alvarez Secord, John Nemunaitis, Merry-Jennifer Markham, Kenneth Nephew, et al. “Abstract 2320: Clinical epigenetic resensitization of platinum-resistant, recurrent ovarian cancer patients with SGI-110, a novel, second-generation, subcutaneously administered hypomethylating agent (HMA).” In Molecular and Cellular Biology. American Association for Cancer Research, 2014. https://doi.org/10.1158/1538-7445.am2014-2320.
    Full Text
  - Havrilesky, Laura Jean, Angeles Alvarez Secord, Jessie A. Ehrisman, Andrew Berchuck, Fidel A. Valea, Paula S. Lee, Stephanie Gaillard, et al. “Relative influence of factors determining a woman’s preference for treatment options in ovarian cancer.” In Journal of Clinical Oncology, 32:5544–5544. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.5544.
    Full Text
  - Nakayama, John, James Edwards, Jessica E. Stine, Elizabeth Pelkofski, Paola A. Gehrlg, Angeles Alvarez Secord, and Linda R. Duska. “Laparoscopy compared to laparotomy in the management of granulosa cell tumors of the ovary.” In Journal of Clinical Oncology, Vol. 32. AMER SOC CLINICAL ONCOLOGY, 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.e16510.
    Full Text Link to Item
  - Roque, Dario R., Stuart Pierce, Kemi Morenikeji Doll, Brittany Davidson, Amanda Lynn Jackson, Emily Meichun Ko, Dominic T. Moore, et al. “Endometrial cancer outcomes in hypertensive women treated with beta-blocker.” In Journal of Clinical Oncology, 32:e16545–e16545. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.e16545.
    Full Text
  - Tew, William P., Michael Sill, D Scott McMeekin, Angeles Alvarez Secord, Albert J. Bonebrake, Jeanne Schilder, Ashley Stuckey, Laurel Rice, Krishnansu Sujata Tewari, and Carol Aghajanian. “A randomized phase II trial of bevacizumab (BV) plus oral everolimus (EV) versus bevacizumab alone for recurrent or persistent epithelial ovarian (EOC), fallopian tube (FTC), or primary peritoneal cancer (PPC).” In Journal of Clinical Oncology, 32:5546–5546. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.5546.
    Full Text
  - Havrilesky, L. J., A. A. Secord, J. Ehrisman, A. Berchuck, F. A. Valea, P. S. Lee, D. Cella, K. Weinfurt, A. P. Abernethy, and S. D. Reed. “Relative Influence of Factors Determining a Woman’s Preference for Treatment Options in Ovarian Cancer: A Discrete Choice Experiment.” In Value in Health, 17:A93–A93. Elsevier BV, 2014. https://doi.org/10.1016/j.jval.2014.03.539.
    Full Text
  - Ko, Emily Meichun, Paige Walter, Leslie Horn Clark, Amanda Lynn Jackson, Jason Franasiak, Laura Jean Havrilesky, Angeles Alvarez Secord, Dominic T. Moore, Paola A. Gehrig, and Victoria Lin Bae-Jump. “The impact of diabetes and obesity on endometrial cancer outcomes.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Stine, Jessica E., Stuart Pierce, Paola A. Gehrig, John Nakayama, Laura Jean Havrilesky, Angeles Alvarez Secord, Wing K. Chiu, Dominic T. Moore, and Kenneth H. Kim. “Recurrence rates in patients with uterine papillary serous cancer with and without breast cancer.” In Journal of Clinical Oncology, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
    Link to Item
  - Siamakpour- Reihani, Sharareh, Chen Jiang, Taylor Turner, Kouros Owzar, Andrew Berchuck, Mark Dewhirst, and Angeles Alvarez Secord. “Abstract 330A: Differential expression of angiogenic genes in invasive high grade serous ovarian carcinomas.” In Clinical Research. American Association for Cancer Research, 2013. https://doi.org/10.1158/1538-7445.am2013-330a.
    Full Text
  - Zighelboim, Israel, Jason D. Wright, Feng Gao, Ashley Stephens Case, L Stewart Massad, David Gardner Mutch, Matthew A. Powell, et al. “Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancer.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
    Link to Item
  - Havrilesky, L. J., R. K. Hanna, M. S. Poniewierski, R. Laskey, A. A. Secord, P. A. Gehrig, M. A. Lopez, et al. “Relationship between relative dose intensity and mortality in women receiving combination chemotherapy for stage III-IV epithelial ovarian cancer.” In Journal of Clinical Oncology, 29:5084–5084. American Society of Clinical Oncology (ASCO), 2011. https://doi.org/10.1200/jco.2011.29.15_suppl.5084.
    Full Text
  - Gray, H. J., A. A. Secord, M. L. Anderson, G. DelPriore, N. E. Tchabo, and J. S. Berek. “A randomized, open-label phase IIb study of maintenence therapy with a MUC-1 dendritic cell vaccine in patients with epithelial ovarian cancer in first or second remission.” In Journal of Clinical Oncology, 28:TPS171–TPS171. American Society of Clinical Oncology (ASCO), 2010. https://doi.org/10.1200/jco.2010.28.15_suppl.tps171.
    Full Text
  - Cantrell, L. A., L. Havrilesky, D. O’Malley, M. Liotta, A. A. Secord, C. Nagel, A. N. Fader, A. Wallace, P. Rose, and P. A. Gehrig. “Effect of treatment of patients with early-stage uterine carcinosarcoma.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - O’Malley, D. M., C. Nagel, L. A. Cantrell, L. Havrilesky, M. Liotta, A Alvarez Secord, A. Nickles, et al. “Improved outcomes in advanced stage uterine carcinosarcoma (mixed mullerian tumor [MMT]).” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.
    Link to Item
  - Fader, A Nickles, D. Starks, P. G. Rose, E. R. Tuller, H. Gibbons, P. A. Gehrig, W. K. Huh, et al. “Early-stage uterine papillary serous carcinoma (UPSC): percentage UPSC, lymphvascular invasion and tumor size are not independent predictors of recurrence.” In Gynecologic Oncology, 112:S72–73. ACADEMIC PRESS INC ELSEVIER SCIENCE, 2009.
    Link to Item
  - Havrilesky, L. J., A Alvarez Secord, D. M. O’Malley, V. Bae-Jump, G. Broadwater, J. Tatagari, N. Hamamci, and P. A. Gehrig. “Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer.” In Gynecologic Oncology, 112:S81–S81. ACADEMIC PRESS INC ELSEVIER SCIENCE, 2009.
    Link to Item
  - Secord, A Alvarez, L. J. Havrilesky, D. M. O’Malley, V. Bae-Jump, N. D. Fleming, G. Broadwater, D. E. Cohn, and P. A. Gehrig. “A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer.” In Gynecologic Oncology, 112:S12–13. ACADEMIC PRESS INC ELSEVIER SCIENCE, 2009.
    Link to Item
  - Secord, A Alvarez, N. Neubauer, L. J. Havrilesky, B. Calingaert, M. Bernardini, A. Bland, and N. Fleming. “The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma.” In Gynecologic Oncology, 112:S91–92. ACADEMIC PRESS INC ELSEVIER SCIENCE, 2009.
    Link to Item
  - Shafer, A., T. A. Ayeni, A. M. Deal, A Alvarez Secord, J. T. Soper, L. J. Havrilesky, L. Van Le, and P. A. Gehrig. “Improved survival with consolidation chemotherapy after adjuvant paclitaxel and carboplatin in advanced epithelial ovarian cancer.” In Gynecologic Oncology, 112:S135–36. ACADEMIC PRESS INC ELSEVIER SCIENCE, 2009.
    Link to Item
  - Lee, P. S., V. Teaberry, A. E. Bland, Z. Huang, A Alvarez Secord, A. Berchuck, and S. K. Murphy. “MAL, a gene associated with survival in epithelial ovarian cancer, is epigenetically regulated.” In Gynecologic Oncology, 108:S125–S125. ACADEMIC PRESS INC ELSEVIER SCIENCE, 2008.
    Link to Item
  - Rubatt, J. M., K. M. Darcy, A. Hutson, S. M. Bean, L. J. Havrilesky, P. S. Lee, L. A. Grace, A. Berchuck, and A Alvarez Secord. “Prognostic relevance of microvessel density in previously untreated, advanced-stage epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.” In Gynecologic Oncology, 108:S20–S20. ACADEMIC PRESS INC ELSEVIER SCIENCE, 2008.
    Link to Item
  - Shafer, A., J. M. Rubatt, T. Ayeni, A. M. Deal, A. A. Secord, J. T. Soper, L. J. Havrilesky, L. Van Le, and P. A. Gehring. “Surgical cytoreduction and dose intensity of adjuvant paclitaxel and carboplatin chemotherapy in advanced epithelial ovarian cancer.” In Gynecologic Oncology, 108:S55–56. ACADEMIC PRESS INC ELSEVIER SCIENCE, 2008.
    Link to Item
  - Herzog, T. J., N. M. Spirtos, J. F. Hines, P. S. Braly, M. Bell, A. A. Secord, P. Rose, B. J. Monk, E. Soltes-Rak, and B. H. Childs. “Preliminary safety and efficacy results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.” In Journal of Clinical Oncology, Vol. 25. AMER SOC CLINICAL ONCOLOGY, 2007.
    Link to Item
  - Berchuck, Andrew, Johnathan M. Lancaster, Edwin S. Iversen, Jingqin Luo, Douglas A. Levine, Jeffrey Boyd, Angeles Alvarez Secord, Jeffrey R. Marks, Joseph R. Nevins, and Holly Dressman. “Most early-stage serous ovarian cancers have gene expression profiles predictive of long-term survival.” In Gynecologic Oncology, 104:S15–16. ACADEMIC PRESS INC ELSEVIER SCIENCE, 2007.
    Link to Item
  - Secord, Angeles Alvarez, John A. Blessing, Deborah Armstrong, Mack N. Barnes, George Lewandowski, and Robert S. Mannel. “Phase II study of cetuximab in combination with carboplatin in patients with relapsed platinum-sensitive ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group study.” In Gynecologic Oncology, 104:S32–S32. ACADEMIC PRESS INC ELSEVIER SCIENCE, 2007.
    Link to Item
  - Jones, E. L., L. J. Havrilesky, A. A. Secord, D. L. Clarke-Pearson, J. T. Soper, F. Valea, R. E. Coleman, and T. Z. Wong. “68.” In International Journal of Radiation Oncology*Biology*Physics, 66:S40–S40. Elsevier BV, 2006. https://doi.org/10.1016/j.ijrobp.2006.07.098.
    Full Text
  - Secord, A Alvarez, L. J. Havrilesky, R. V. Higgins, L. R. Nycum, M. F. Kohler, L. E. Puls, R. Holloway, J. T. Soper, F. A. Valea, and A. Berchuck. “A comparison of combination docetaxel/carboplatin versus sequential docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.” In Journal of Clinical Oncology, 24:278S-278S. AMER SOC CLINICAL ONCOLOGY, 2006.
    Link to Item
  - Rabbani, Z. N., J. P. Kirkpatrick, F. K. Salahuddin, R. C. Bentley, A. A. Secord, C. S. Greenberg, L. J. Havrilesky, Z. Vujaskovic, E. Jones, and M. W. Dewhirst. “Tissue transglutaminase expression in early-stage cervical cancer.” In International Journal of Radiation Oncology Biology Physics, 66:S167–S167, 2006. https://doi.org/10.1016/j.ijrobp.2006.07.331.
    Full Text Link to Item
  - Mutch, D., M. Orlando, T. Teneriello, A. Gordon, S. McMeekin, T. Goss, D. Scribner, R. Naumann, A Alvarez Secord, and Y. Wang. “Randomized phase III trial of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLDOX) for patients (pts.) with platinum-resistant (pt-r) ovarian cancer (oc) undergoing second or third-line chemotherapy (ct).” In Ejc Supplements, 3:262–262. PERGAMON-ELSEVIER SCIENCE LTD, 2005.
    Link to Item
  - Berchuck, A., A. A. Secord, L. J. Havrilesky, R. Wenham, J. T. Soper, and D. L. Clarke-Pearson. “Phase I/II trial of combination topotecan and vinorelbine in patients with refractory gynecologic cancer.” In Journal of Clinical Oncology, 22:487S-487S. AMER SOC CLINICAL ONCOLOGY, 2004.
    Link to Item
  - Secord, A. A., E. Jones, C. A. Hahn, L. J. Havrilesky, J. T. Soper, A. Berchuck, D. L. Clarke-Pearson, and L. R. Prosnitz. “Phase I/II trial of intravenous liposomal doxorubicin and whole abdomen hyperthermia in patients with refractory ovarian cancer.” In Journal of Clinical Oncology, 22:471S-471S. AMER SOC CLINICAL ONCOLOGY, 2004.
    Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.

Education, Training, & Certifications

Previous Appointments & Affiliations

Selected Grants

External Relationships

Selected Publications

Academic Articles

Book Sections

Conference Papers